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ABSTRACT 
Introduction: Antiepileptic-antidepressant combinations are frequently used by clinicians; their 
pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions (DIs) have not been well-
studied but are frequently likely to be clinically relevant. 
 
Areas covered: This article provides a comprehensive review of PK DIs between antiepileptics and 
antidepressants. In the absence of PD DI studies, PD information on pharmacological mechanisms 
and studies on efficacy and safety of individual drugs are reviewed.   
 
Expert opinion: The clinical relevance of the inductive properties of carbamazepine, phenytoin, 
phenobarbital and primidone, and the inhibitory properties of valproic acid and some 
antidepressants are well understood; correction factors are provided if appropriate DI studies have 
been completed. More PK studies are needed for:  i) antiepileptics with potent inductive effects for 
all recently approved antidepressants; ii) high doses of mild CYP3A4 inducers, such as clobazam, 
eslicarbazepine, oxcarbazepine, rufinamide and topiramate for reboxetine and vilazodone; iii) 
valproate  as a possible inhibitor, mild inducer, or both a mild inducer and competitive inhibitor of 
some antidepressants; and  iv) inhibitory effects of long-term fluoxetine use on clobazam, 
lacosamide, phenobarbital, primidone, carbamazepine, felbamate, tiagabine, and zonisamide.  
Possible synergistic or additive beneficial PD DIs in generalized anxiety disorder, chronic pain, 
migraine prophylaxis, weight control, and menopausal symptoms need study. 
 
Keywords: antiepileptics; antidepressants; drug interactions; pharmacodynamics; 
pharmacokinetics.    
 
  
 
 
Highlights box 
-Pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions (DIs) in antiepileptic and 
antidepressant combinations have not been well-studied but are frequently likely to be clinically 
relevant.  
-More PK studies are needed for establishing dose-correction factors for i) antiepileptics with 
potent inductive effects for all recently approved antidepressants; ii) high doses of clobazam, 
eslicarbazepine, oxcarbazepine, rufinamide and topiramate, for reboxetine and vilazodone; iii) 
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fluvoxamine as an inhibitor of clobazam, lacosamide, phenobarbital, and primidone; iv) fluoxetine 
as an inhibitor after several months of co-prescription for clobazam, lacosamide, phenobarbital, 
primidone, carbamazepine, felbamate, tiagabine, and zonisamide; v) high doses of sertraline as an 
inhibitor of valproate and lamotrigine; and vi) tricyclic antidepressants as inhibitors of lacosamide 
and clobazam.   
-PD DI studies on antiepileptic-antidepressant combinations, information on the pharmacological 
mechanism and the efficacy and safety studies of individual drugs is provided to raise awareness of 
the potential for PD DIs.  
-Possibly synergistic or additive beneficial PD DIs are: i) adding pregabalin to an antidepressant for 
generalized anxiety disorder; ii) combining carbamazepine, gabapentin, oxcarbazepine, or 
pregabalin with serotonin and noradrenaline reuptake inhibitors (SNRIs), or tricyclic 
antidepressants (TCAs) for chronic pain; iii) combining topiramate or valproic acid with 
amitriptyline or venlafaxine for migraine prophylaxis; iv) combining bupropion and zonisamide or 
topiramate  for weight control; and v) combining gabapentin with SNRIs or selective serotonin 
reuptake inhibitors (SSRIs) for menopausal symptoms.   
-Possibly synergistic or additive harmful PD DIs are some combinations of antiepileptics and 
antidepressants increasing the risk for sedation, weight gain, hyperlipidemia, nausea, urinary 
retention, hyponatremia, torsades de pointes,  hepatic failure, hemorrhages,  heat stroke and 
osteoporosis.   
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1. Introduction 
Antiepileptic drugs are traditionally divided into first- and second-generation compounds. In 
addition to the treatment of epilepsy, antiepileptics are extensively prescribed for the management 
of several non-epileptic neurological and psychiatric conditions [1, 2]. In general, compared to the 
older drugs, newer antiepileptics have more advantageous pharmacokinetic characteristics, a wider 
therapeutic index, a more favorable tolerability and safety profile, and lower potential for drug 
interactions (DIs). For these reasons, despite the lack of definitive studies directly comparing the 
efficacy of first-generation and second-generation agents [3, 4], newer antiepileptics, particularly 
lamotrigine, levetiracetam and oxcarbazepine, have partially replaced older compounds in 
developed countries. Among first-generation agents, valproate is the only drug still prescribed as a 
first-line drug in males and non-fertile females. It is not a first choice in females of fertile age due to 
its teratogenicity potential.   
Currently available antidepressants include older or classic agents, such as tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), and newer antidepressants, 
such as selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake 
inhibitors (SNRIs) and other antidepressants with varying mechanisms of action 5. Over the past 
two decades, the newer antidepressants, particularly SSRIs, have become the drugs of choice for the 
management of depressive disorders, mainly because of their improved tolerability and safety 
profile as compared to TCAs. Antidepressant drugs are also widely used for the treatment of other 
psychiatric conditions including anxiety disorders, obsessive-compulsive disorder (OCD), eating 
disorders, and various forms of chronic pain such as diabetic neuropathic pain and fibromyalgia 5. 
 Antiepileptics and antidepressants are often prescribed together in patients with several 
heterogeneous conditions. Combined use is more likely for more recent compounds, which often 
exhibit a wider spectrum of indications. The incidence of depressive disorders in epileptic patients 
is estimated to be 30%–70% in their lifetime [6, 7].  Therefore, due to this strict relationship 
between epilepsy and mood disorders, antidepressants are frequently co-prescribed in patients with 
epilepsy [8-11]. Valproate, carbamazepine and lamotrigine, when used as mood stabilizers, are 
frequently associated with antidepressants for the treatment of bipolar disorder [12-15]. Evidence 
for efficacy in bipolar disorder also exists for oxcarbazepine [16]. International guidelines for the 
treatment of neuropathic pain also include combined treatment with antidepressants and 
antiepileptics [17]. Pregabalin and gabapentin are commonly prescribed with a TCA or SNRI for 
this condition [18, 19]. Pregabalin is approved for the treatment of generalized anxiety disorder in 
Europe and articles frequently recommend adding it to antidepressants for the treatment of 
generalized anxiety disorder with comorbid mood depression [20, 21]. Moreover, antidepressants 
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may be co-prescribed with topiramate and valproate for migraine prophylaxis, or exclusively to 
treat migraine comorbid with depression [22, 23]. 
Considering the frequent co-prescription of antiepileptics and antidepressants, it is essential 
for clinicians to be aware of the potential DIs between these compounds. The consequences of a DI 
can be either beneficial, if the interaction results in increased therapeutic efficacy or reduced risk of 
adverse drug reactions (ADRs), or harmful, if it leads to decreased efficacy or enhanced toxicity of 
one or more of the administered medications. Based on their mechanisms, DIs can be classified into 
two main categories, pharmacokinetic (PK) and pharmacodynamic (PD). 
In recent years, a number of comprehensive reviews of clinically relevant pharmacokinetic 
DIs involving antiepileptics 24-28 or antidepressants 29-33 or combinations [34, 35] have been 
published. The aim of the present article is to provide an updated review of clinically significant 
DIs between antiepileptics and antidepressants including not only PK DIs but also PD DIs.  
Articles for this review were obtained from a PubMed search with no time limit. Searches 
were performed for each of the antiepileptics and antidepressants. Only articles published in peer-
reviewed journals were included, while meeting abstracts were excluded.  Information was also 
obtained from the individual product inserts of each antiepileptic or antidepressant. Additional DI 
information was also obtained from citations of the articles that were retrieved during our search, 
and these were also included in our review. This search was beyond the articles previously found 
and listed in the authors’ published literature reviews and DI studies. 
 
2. Basic mechanisms of DIs between antiepileptics and antidepressants 
 
2.1 PK DIs 
PK DIs consist of changes in the absorption, distribution, metabolism or excretion of a drug 
and/or its metabolite(s) after the addition of another drug. These DIs are associated with a 
modification in plasma concentration of either the drug or its metabolite(s) and usually are easily 
verified by therapeutic drug monitoring (TDM). PK parameters of antiepileptics and antidepressants 
are summarized in Tables 1 and 2, respectively.  
To our knowledge, no clinically relevant DI has been described so far during at the 
absorption phase or protein binding [36-37] between compounds of these two drug classes.   
The vast majority of clinically important PK DIs between antiepileptics and antidepressants 
occur at a metabolic level and usually involve the hepatic cytochrome P450 (CYP) system and, to a 
lesser extent, the uridine diphosphate glucuronosyltransferase (UGT) system 38. Knowledge of 
the properties of the major drug-metabolizing enzymes with identification of substrates, inhibitors, 
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and inducers of different CYP isoforms can provide some clues to clinicians as to the likelihood of 
a clinically relevant DI occurring [38].  In principle, concomitant treatment with drugs metabolized 
by the same enzyme or coadministration of a drug with another medication acting as an inhibitor or 
inducer involves a DI risk.  A number of drug-related (i.e., potency and concentration/dose of the 
inhibitor/inducer, therapeutic index of the substrate, extent of metabolism of the substrate through 
the affected enzyme, presence of active metabolites), patient-related (i.e., age, genetic 
predisposition) and environmental factors (i.e., smoking)  will then influence the potential 
occurrence, magnitude, and clinical significance of a metabolic DI  [37]. As shown in Tables 1 and 
2, most antiepileptics (with the exception of gabapentin, pregabalin and vigabatrin) and 
antidepressants are extensively metabolized via CYPs or UGTs. As many compounds of these two 
therapeutic classes share common metabolic pathways, potential DIs may be anticipated. 
Furthermore, antiepileptics may be involved in metabolically-based DIs because they act as 
inhibitors or inducers of various drug-metabolizing systems. Among first-generation agents, 
carbamazepine, phenytoin, phenobarbital and primidone (enzyme-inducing antiepileptics) induce 
the activity of CYP1A2, CYP2C9, CYP2C19 and CYP3A4, as well as UGTs and epoxide 
hydrolase. Valproic acid is a broad-spectrum inhibitor of various drug-metabolizing enzymes 
including CYP2C9 and UGTs and, recently, some inductive effects have been demonstrated. The 
newer antiepileptics are associated with limited enzyme-inducing potential compared with older-
generation compounds. However, clobazam, eslicarbazepine, felbamate, oxcarbazepine (at dosages 
≥ 1200 mg/day), rufinamide and topiramate (at dosages ≥ 400 mg/day) can induce the activity of 
CYP3A4 and, possibly, some UGTs (Table 1). Some of the newer antiepileptics may at times act as 
enzyme inhibitors. Eslicarbazepine, felbamate, oxcarbazepine and topiramate are weak inhibitors of 
CYP2C19, while stiripentol is a potent inhibitor of CYP1A2, CYP2C19, CYP2D6 and CYP3A4. 
Concerning older antidepressants, in vitro evidence indicates that TCAs may inhibit the activity of 
CYP2C19 (moderately) and CYP2D6 (weakly) [39].  On the other hand, some newer antidepressant 
agents including fluoxetine, fluvoxamine, paroxetine, duloxetine and bupropion, act as potent or 
moderate inhibitors of various CYPs and may therefore impair the elimination of antiepileptic 
agents metabolized via these isoforms 29, 31, 32.    
PK DIs between antiepileptics and antidepressants may theoretically occur during the 
excretion phase. While some newer antiepileptics such as gabapentin, pregabalin, vigabatrin, 
levetiracetam and topiramate are eliminated predominantly through the kidneys, antidepressants are 
predominantly eliminated by drug metabolism. Only desvenlafaxine and milnacipran are largely 
excreted unchanged in the urine. So far, there are no reports of clinically significant DIs between 
antiepileptics and antidepressants at the renal excretion level.  
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PK DIs between antiepileptics and antidepressants may also involve drug transporters, in 
particular, P-glycoprotein (P-gp), which plays an important role in the absorption, distribution and 
excretion of a wide variety of therapeutic agents 40. As some antiepileptics and antidepressants 
may be substrates, inducers or inhibitors of P-gp 41-43, it can be speculated that some DIs 
between antiepileptics and antidepressants previously believed to be CYP-mediated are now also 
considered to be due to the modulation of multidrug-transporters. 
 
2.1.1 PKs of inducer antiepileptics and endogenous substrates 
 Some ADRs from potent inducers may be explained by the induction of endogenous 
compounds [44-53], but they may manifest only after the organism has not been able to compensate 
for these disturbances in homeostasis present for months or years (Figure 1),  
 
2.2 PD DIs 
The importance of PD mechanisms of antiepileptics and antidepressants are often under-
estimated in most articles reviewing DIs. This subsection briefly lists the PD properties of 
antiepileptics and antidepressants; they are described more comprehensively in Figures 2 to 5 and 
their detailed footnotes. At the end of this section, a subsection comments on the types of PD DIs. 
 
2.2.1 PDs of antiepileptics 
Figure 2 summarizes the mechanism of action of antiepileptics in epilepsy, bipolar disorder, 
anxiety, pain, migraine prophylaxis, weight loss and other indications. Figure 3 summarizes the 
mechanism of action of antiepileptics associated with major safety issues.  
 
2.2.2 PDs of antidepressants 
Figure 4 summarizes antidepressant mechanisms of action in several disorders including 
depression, OCD, anxiety, pain, weight loss and other indications.  Textbooks usually report that 
the majority of antidepressants act by inhibiting reuptake transporters but the chronology of 
reuptake inhibition does not match the chronology of antidepressant response 5, 54. Only four 
TCAs, amitriptyline, clomipramine, imipramine, and nortriptyline, are described in the figures and 
tables. Figure 4 lists SSRIs, SNRIs and other newer antidepressants with different mechanisms.  
Nefazodone and MAOIs are not included in this article. Figure 5 summarizes antidepressant 
mechanisms of action associated with major safety issues.  
 
2.2.3. Pharmacological knowledge and PD DIs 
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PD DIs result in a modification of the pharmacological action of a drug by a direct effect on 
its site of action or, alternatively, by interfering with another physiological mechanism related to 
drug action. Therefore, they occur without any change in the plasma concentration and are more 
difficult to recognize and quantify than PK DIs. PD DIs can be classified as additive (i.e., equal to 
the sum of the effects of the individual drugs), synergistic (i.e., the combined effects are greater 
than expected from the sum of individual effects) or antagonistic (i.e., the combined effects are less 
than additive) [37]. They can involve beneficial effects (increased efficacy and/or safety) or harmful 
effects (decreased efficacy and/or safety). 
 
3. Specific DIs between antiepileptics and antidepressants  
3.1 PK DIs 
3.1.1 Effect of antiepileptics on the PKs of antidepressants  
First-generation antiepileptics  
The first-generation antiepileptics, namely carbamazepine, phenytoin, phenobarbital and 
primidone, may induce antidepressant metabolism, as they are powerful inducers of several drug-
metabolizing enzymes including CYPs, specifically CYP1A2, CYP2A6, CYP2B6, CYP2C9, 
CYP2C19, CYP3A4, as well as UGTs such as UGT1A1, UGT2B7, and UGT2B15. 
Early PK studies [34] have repeatedly documented that, concomitant treatment with 
enzyme-inducing antiepileptics was associated with a decrease in plasma concentrations of various 
TCAs. Because the demethylation of TCAs is catalyzed by multiple isozymes, including CYP2C19 
and, to a lesser extent, CYP1A2, CYP2C9 and CYP3A4 [55, 56], induction of these isoforms is the 
most likely explanation for the observed PK changes. Another major enzyme contributing to the 
metabolism of TCAs, in particular to the hydroxylation reactions, CYP2D6 is generally regarded to 
be non-inducible, even though in two formal kinetic studies the 2-hydroxylation of desipramine, a 
reaction primarily catalyzed by CYP2D6, was found to be accelerated by carbamazepine and 
phenobarbital [57, 58]. In a subsequent investigation in 13 patients with major depression stabilized 
with imipramine, the addition of carbamazepine, at a dose of 400 mg/day for two weeks, caused a 
significant decrease in mean steady-state concentrations of imipramine and its active metabolite 
desipramine, by 42% and 41%, respectively, while the free concentrations of both imipramine and 
desipramine increased [59]. The authors speculated that carbamazepine may affect not only the 
metabolism of imipramine and desipramine, but also their protein binding. Irrespective of the 
mechanism of the interaction, the decrease in plasma concentrations of TCAs is likely to have 
clinical implications and individual patients on long-term treatment with enzyme-inducing 
antiepileptics may require higher doses to achieve an optimal therapeutic response.  
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 Regarding SSRIs, phenobarbital, phenytoin and carbamazepine have been reported to 
decrease by about 25% the plasma levels of paroxetine, probably as a result of accelerated 
metabolism [60, 61]. Administration of carbamazepine, an inducer of CYP3A4, was associated with 
a marked decrease in plasma sertraline concentrations in two patients, resulting in lack of 
antidepressant efficacy [62]. In an open pilot study involving 6 patients with major depression 
stabilized on citalopram (40-60 mg/day), a 4-week augmentation therapy with relatively low doses 
of carbamazepine (200-400 mg/day) caused a significant decrease in plasma concentrations of S-
citalopram and R-citalopram by 27 and 31% (both, p < 0.05), respectively [63]. This effect was 
attributed to nonstereoselective induction of CYP3A4-mediated N-demethylation of citalopram by 
carbamazepine. 
Carbamazepine, a CYP3A4 inducer, 200 mg twice a day for 32 days, caused a 20% decrease 
in milnacipran plasma concentrations [64]. Two PK investigations evaluated the reciprocal 
interaction between the new antidepressant mirtazapine (30 mg/ day) and carbamazepine (400 
mg/day) or phenytoin (200 mg/day) in healthy subjects under steady-state conditions [65, 66]. In 
the first study, coadministration with carbamazepine in 24 healthy volunteers caused a mean 
reduction by 39% in the peak plasma concentration (Cmax) of mirtazapine and by 61% in the area 
under the plasma concentration-time curve (AUC) [65]. Similarly, addition of phenytoin to 17 
healthy male subjects resulted in a mean decrease of the Cmax of mirtazapine by 33% and in its 
AUC by a 47% decrease [66]. The reduction in mirtazapine concentrations is presumably due to 
induction of CYP3A4-mediated metabolism of mirtazapine by carbamazepine and phenytoin. 
Carbamazepine may also induce the biotransformation of bupropion, a new antidepressant which 
inhibits the reuptake of noradrenaline and dopamine. In a study involving 12 patients with mood 
disorders given a single 150 mg dose of bupropion, addition of carbamazepine, at a mean dose of 
942 mg/day, was found to decrease the Cmax of bupropion by 87% (p<0.001) and its AUC by 90% 
(p<0.001) [67]. Carbamazepine increased the AUC of its metabolite hydroxybupropion by 50% 
(p<0.05). As hydroxybupropion may contribute to therapeutic or adverse effects, the clinical 
significance of this DI has not yet been established. A case report described two patients with low 
serum concentrations of reboxetine in relation to the dose during carbamazepine or phenobarbital 
treatment probably mediated by CYP3A4 induction [68].  
Valproate has traditionally been considered a broad-spectrum metabolic enzyme inhibitor. It 
inhibits CYP2C9 competitively, CYP2C19 and CYP3A4 weakly and has no effects on CYP1A2, 
CYP2D6, and CYP2E1. It inhibits UGT enzymes (UGT1A4 and UGT2B7) [37]. However, a 
human hepatocyte study surprisingly demonstrated that valproate may induce some enzymes 
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(CYP3A4 and P-gp gene expression) [69]. Moreover, recent clinical studies indicate that valproate 
may behave as a mild inducer in some circumstances [70].  
Two studies have reported a 50% to 60% elevation in plasma amitriptyline and nortriptyline 
concentrations in depressed patients comedicated with valproate [71, 72]. In a PK investigation in 
15 healthy subjects, the mean AUC and Cmax for the sum of amitriptyline and nortriptyline 
increased by 42% and 19%, respectively, after the addition of valproate [73]. Moreover, an 
elevation of serum nortriptyline or clomipramine concentrations in association with valproate 
comedication was observed in case reports [74-75]. Severe ADRs associated with a considerable 
increase in serum levels of TCAs during valproate treatment has been described in case reports [76-
78]. Unterecker et al. [79] have recently evaluated the influence of valproic acid on amitriptyline 
and nortriptyline serum concentrations by a retrospective analysis of TDM data under naturalistic 
conditions. When comparing 33 patients receiving amitriptyline in combination with valproic acid 
versus 33 patients on amitriptyline monotherapy, dose-corrected serum concentrations of 
amitriptyline, nortriptyline and their sum were significantly higher (p<0.001), by 67%, 128% and 
94%, respectively, in patients on comedication. The interaction between valproate and TCAs may 
be explained by an inhibitory effect of valproate on CYP2C9 and, possibly, CYP2C19 and 
CYP3A4, which play a role in the biotransformation of TCAs [55, 56]. In a subsequent study based 
on the same TDM database, the same authors [80] examined the potential DI between valproic acid 
and doxepin and venlafaxine, an SNRI agent. The mean dose-corrected serum concentrations of 
doxepin plus N-doxepin in 16 patients who received valproic acid comedications were significantly 
higher (by 124%, p<0.01) than in the matched controls of patients on doxepin alone. The mean 
dose-corrected serum concentrations of venlafaxine plus O-desmethylvenlafaxine in 41 patients 
receiving valproic acid comedications did not differ significantly from those of the matched 
controls. However, the dose-corrected serum concentrations of the active metabolite O-
desmethylvenlafaxine were significantly higher (by 27%, p<0.02) in patients treated with the 
combination of valproic acid with venlafaxine. The increase in serum concentrations of doxepin 
plus N-doxepin is attributed to the inhibitory effect of valproate on CYP2C9 [81]. To explain the 
elevation of serum concentrations of O-desmethylvenlafaxine, the authors speculate that the 
inhibition of the CYP2C9-mediated N-demethylation of venlafaxine by valproate may lead to a 
stronger O-demethylation and, as a consequence, to higher serum levels of O-desmethylvenlafaxine 
[82]. Unlike carbamazepine, valproic acid did not affect the metabolism of bupropion in patients 
with depression [67]. 
 
Second-generation antiepileptics  
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Compared with first-generation agents, second-generation antiepileptics have a lower 
propensity to cause PK DIs. To our knowledge, no systematic study has documented the effect of 
newer antiepileptics on the disposition of antidepressants. Baird [83] described a case of a possible 
clomipramine induction by oxcarbazepine.  
 
3.1.2 Effect of antidepressants on the PKs of antiepileptics 
Older antidepressants 
While some antiepileptics can profoundly affect TCA plasma concentration, there is little 
evidence that TCAs can influence the pharmacokinetics of anticonvulsants. One study showed that 
nortriptyline coadministration produced a small increase in phenytoin levels [34], while in another 
report plasma phenytoin concentration was found to increase in two patients during treatment with 
imipramine and to return to baseline after its discontinuation [34]. 
 
Newer antidepressants 
Fluoxetine and its metabolite norfluoxetine are potent inhibitors of CYP2D6 and moderate 
inhibitors of CYP2C9, while they mildly to moderately affect the activity of CYP2C19 and 
CYP3A4 31, 84. Case reports indicated that concurrent use of fluoxetine and phenytoin can result 
in significantly increased phenytoin serum levels leading to toxicity [85-87].  This DI has been 
attributed to the moderate inhibitory effect of fluoxetine on the CYP2C9-mediated 
biotransformation of phenytoin [88]. Fluoxetine may also impair the elimination of carbamazepine, 
as documented by case reports after the addition of fluoxetine [89, 90]. Conversely, no changes in 
steady-state carbamazepine levels were observed in eight epileptic patients on a chronic treatment 
with carbamazepine (800-1600 mg/day) after a 3-week coadministration with fluoxetine, 20 
mg/day, suggesting that inhibition of CYP3A4-mediated carbamazepine metabolism might occur 
only at higher fluoxetine doses [91] or require more than 3 weeks to manifest, due to the long half-
life of norfluoxetine.  Early case reports had documented that the addition of fluoxetine to an 
ongoing treatment with valproic acid may increase steady-state plasma concentrations of valproic 
acid, along with showing signs of toxicity [92-94]. The most plausible explanation for the raised 
valproic acid levels is inhibition of CYP2C9 by fluoxetine. In a large routine TDM program for 
lamotrigine, dose-normalized serum concentrations of lamotrigine were significantly lower (by 
39%) in 15 patients taking fluoxetine than in the reference group of 224 subjects on lamotrigine 
alone [95]. As fluoxetine is not a known enzyme inducer, but is a potent inhibitor of CYP enzymes, 
the authors speculate that fluoxetine or its metabolite norfluoxetine may induce the UGT enzymes 
involved in the glucuronidation of lamotrigine.  
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Paroxetine is a potent inhibitor of CYP2D6, while it only minimally affects other CYPs 31, 
84. In a single-blind, placebo-controlled, cross-over study of 20 patients with epilepsy, stabilized 
on phenytoin, carbamazepine or valproic acid, addition of paroxetine, 10-30 mg/day for 16 days, 
caused no significant changes in plasma concentrations of these antiepileptic drugs [61].  
Fluvoxamine influences the activity of various CYP isoenzymes; it is a potent inhibitor of 
CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4, while it affects 
CYP2D6 activity only slightly 31, 84. Being an inhibitor of different CYP isoforms, fluvoxamine 
may impair the elimination of various antiepileptics. There is conflicting evidence for a metabolic 
DI between fluvoxamine and carbamazepine. Although case reports have documented that 
fluvoxamine increased carbamazepine levels with associated symptoms of carbamazepine toxicity 
[96, 97], one study of seven epileptic patients stabilized on carbamazepine (800-1600 mg/day) 
found no such increase in carbamazepine levels after three weeks of coadministration with 
fluvoxamine, 100 mg/day [91]. A case report documented a 3-fold increase in serum concentrations 
of phenytoin after administration of fluvoxamine [98]. This pharmacokinetic change was explained 
as a result of inhibition of both CYP2C9 and CYP2C19 by fluvoxamine.  
Sertraline is a mild to moderate in vitro inhibitor of CYP2D6 and a weak inhibitor of the 
other CYP isoenzymes 31, 84. Two RCTs, using double-blinding and placebo in healthy 
volunteers, have documented that sertraline, at a dose of 200 mg/day for 17 days, did not affect the 
pharmacokinetics of carbamazepine (400 mg/day for 32 days; n =14) and phenytoin (300 mg/day 
for 24 days; n = 30), substrates for CYP3A4 and CYP2C9, respectively [99, 100].  On the other 
hand, in a patient with bipolar depression treated with valproate, the addition of sertraline (100 
mg/day) resulted in a 3-fold elevation in serum valproic acid concentration associated with signs of 
valproate intoxication [101]. A clinically relevant PK DI may also occur between sertraline and 
lamotrigine, a new antiepileptic which is predominantly metabolized by glucuronide conjugation. A 
two-fold increase in plasma lamotrigine concentration associated with symptoms of toxicity was 
observed in two epileptic patients 6 weeks after the addition of a low dose of sertraline, 25 mg/day 
[102]. In a recent study aimed at evaluating the potential DI between sertraline and lamotrigine, 
dose-corrected concentrations of lamotrigine were slightly, but not significantly, higher (by 18%) in 
7 patients treated with both drugs in combination than in the 44 patients receiving only lamotrigine 
[103]. 
Citalopram and its active S-enantiomer, escitalopram, are weak in vitro inhibitors of 
CYP2D6 and are negligible inhibitors of CYP1A2, CYP2C9, CYP2C19 and CYP3A4 104, 105. 
Due to their minimal effect on drug-metabolizing enzymes, citalopram and escitalopram are not 
expected to cause clinically relevant DIs with antiepileptic drugs. In an open-label investigation in 
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12 healthy volunteers, the addition of citalopram, 40 mg/day for 14 days, to carbamazepine, 
administered at the dose of 400 mg/day for 35 days, did not alter the steady-state PK parameters of 
carbamazepine and its active epoxide metabolite [106].   
According to two investigations in healthy subjects, mirtazapine (30 mg/ day) had no effect 
on PK parameters of both carbamazepine and phenytoin [65, 66]. 
Anecdotal evidence indicates that bupropion may inhibit the metabolism of phenytoin and 
valproate [107].  On the other hand, in a randomized, open-label, two-way crossover study in 12 
healthy subjects, PK parameters of a single oral dose of 100 mg lamotrigine were not affected by 
steady-state bupropion, 150 mg twice/day [108].   
 
3.2 PD DIs 
3.2.1. PD DIs that increase efficacy 
Pharmacodynamic drug interactions are rarely systematically studied, but there is some 
limited literature supporting the theory that the combination of antiepileptic-antidepressants may 
have additive and/or synergistic effects for treatment-resistant depression, anxiety, pain, migraine 
prophylaxis and weight loss. 
There are a few studies on the possible role of some antiepileptics for potentiating 
antidepressants in major depressive disorder. They provide suggestive evidence of the beneficial 
effects of adjunctive carbamazepine, lamotrigine, and valproate, particularly in patients taking 
antidepressants for recurring major depressive disorder with prominent irritability or agitation [109] 
but augmentation strategies, including lithium and antipsychotics, are usually preferred [110]. 
 Pregabalin has been approved for generalized anxiety disorder in Europe. A RCT indicated 
that adjunctive therapy with pregabalin in patients with a partial response to antidepressants in 
generalized anxiety disorder was more effective than placebo [20] and this augmentation strategy is 
recommended by a recent guideline [111]. 
 Different antiepileptics and antidepressants are used as alternatives to analgesic opioids for 
the treatment of chronic pain including fibromyalgia, painful diabetic neuropathy, postherpetic 
neuralgia, neuropathic pain and painful neuropathy [112; Figures 3 and 5]. Clinicians and some of 
the pain guidelines [112] recommend combinations of antiepileptics and antidepressants, as they 
may work using different analgesic mechanisms. The number of RCTs demonstrating greater 
efficacy of the antiepileptic-antidepressant combinations than the individual drugs is limited and 
includes the combination of nortriptyline and gabapentin for neuropathic pain [113], and low-dose 
pregabalin and low-dose antidepressants as adjunctive to opioids for intractable painful bone 
metastasis [114]. 
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For migraine prophylaxis, meta-analyses support the efficacy of approved drugs including 
topiramate and valproate [115, 116] and off-label TCAs, particularly amitriptyline [115, 117].  
There is limited evidence for the use of some other antidepressants, including venlafaxine [115], but 
clomipramine is considered ineffective in migraine prophylaxis [23]. Guidelines do not comment 
on drug combinations for migraine prophylaxis [23], but clinicians use them.  A recent RCT 
obtained a response of 37% in monotherapy versus 78% in the combination of topiramate and 
nortriptyline [118].  
Both bupropion and zonisamide have been associated with weight loss but probably have 
different mechanisms of action (Figures 3 and 5). An article reviewing RCTs using this 
combination suggested that the combination may have additive effects [119], but the RCTs have not 
yet been published. 
 Some articles implied the possibility of additive- and/or synergistic-type PD DIs between 
antiepileptics and antidepressants for two unapproved indications: menopausal vasomotor 
symptoms (Figures 2 and 4) and treatment-resistant OCD.    
 Hormonal replacement has been the treatment of menopausal hot flashes but there is 
increased concern about its risk, leading to an increased use of non-hormonal therapies for 
vasomotor symptoms (hot flashes and night sweats) in patients with natural or iatrogenically-
induced menopause. Gabapentin and some antidepressants, SSRIs and SNRIs, have been studied 
and appear to be better than placebo for menopausal symptoms (Figure 2 and 4). No RCT with 
combined treatment has been published and a recent cross-over RCT [120] does not address the 
combined effects.   
There are few RCTs with antiepileptics in OCD, but one [121] suggests that lamotrigine 
may potentiate the effects of serotonergic reuptake inhibitors in treatment-resistant OCD, possibly 
due to its glutamatergic effects. A recent guideline recommended SSRI augmentation with 
lamotrigine or topiramate as one of the options after initial SSRI non-response in OCD [111]. 
 
3.2.2. PD DIs that decrease efficacy  
The literature provides some support for an antagonistic PD DI for antidepressants in bipolar 
disorder maintenance. There is very limited RCT data on maintenance treatment after bipolar 
depression [122], but there is general agreement that some antidepressants may increase the switch 
to mania, whereas bupropion and SSRIs may have fewer risks than TCAs and SNRIs [123]. A 
meta-analysis suggested that mood stabilizers may not prevent the switch to mania induced by 
antidepressants, but too few studies have been conducted to establish certainty [124]. Future studies 
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will need to verify whether or not antidepressants decrease the mood-stabilizing properties of mood 
stabilizers by increasing mania-switching [125].  
 Figure 3 indicates depression is considered a common ADR to phenobarbital, primidone, 
topiramate and vigabatrin. These antiepileptics should be used very cautiously in patients with a 
history of depression. Other antiepileptics associated with depression, but less frequently, are 
felbamate, levetiracetam, tiagabine and zonisamide. Although there are no studies supporting this, it 
is pharmacologically reasonable to think that any of these antiepileptics can decrease or eliminate 
the antidepressant effects in patients taking antidepressants.        
 Figure 5 indicates that bupropion and TCAs can decrease the seizure threshold and, as a 
matter of fact, they have been associated with seizures in patients without history of epilepsy [126]. 
A meta-analysis of RCTs suggested that other newer antidepressants, which were combined in the 
same group for statistical analysis, appeared to have less seizure risk than placebo [127]. Fluoxetine 
animal studies suggest that it may have anti-seizure activity and can potentiate valproate 
anticonvulsant effects [128]. In summary, bupropion and TCAs (maprotiline may be the worst) 
should not be prescribed to epileptic patients with poor seizure control, since they can decrease the 
efficacy of antiepileptics.     
 
3.2.3. PD DIs that increase safety 
Topiramate and zonisamide can decrease weight when taken with antidepressants associated 
with weight gain (amitriptyline, mirtazapine, paroxetine) but there are no published studies. 
Bupropion can decrease weight when taken with antiepileptics associated with weight gain but, as 
previously described, it had the potential of decreasing the seizure threshold.  
Antiepileptics in some peculiar circumstances may decrease the risk of arrhythmias 
associated with antidepressants. Phenytoin may have beneficial effects on TCA overdoses [129]. 
Rufinamide is an unusual drug in the sense that it has been definitively associated with dose-
dependent reduction of QT interval [130] and has the potential to decrease QTc prolongations in 
patients with SSRI-induced QT prolongations. 
 
3.2.4. PD DIs that decrease safety 
 Non-studied PD DIs possibly associated with specific antidepressant compounds in 
combination with antiepileptics may include increased risk for sedation, weight gain and metabolic-
associated symptoms, nausea and urinary symptoms.   
Sedation is a very common ADR for antiepileptics (except for felbamate, lacosamide, 
lamotrigine and tiagabine, which may have a frequency <10% in RCTs). Antidepressants with 
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clinically relevant antagonism of histamine 1 (H1) receptors including TCAs, trazodone and 
mirtazapine are likely to increase the risk of sedation in patients taking antiepileptics; therefore, 
prescribers may want to consider other antidepressants in patients taking antiepileptics. 
The compounds associated with weight gain include among antiepileptics, carbamazepine, 
gabapentin, pregabalin, retigabine, and valproate, and among antidepressants [49], some TCAs, 
mirtazapine and paroxetine [131]. Therefore, the combination of any of these antiepileptics 
associated with weight gain may have additive effects. The only antidepressant clearly associated 
with hyperlipidemias is mirtazapine [132]. It should be cautiously added to potent inducer 
antiepileptics that have been associated with hyperlipidemias (carbamazepine, phenobarbital, 
phenytoin, and primidone; Figure 1).     
 Nausea and vomiting are common ADRs in almost all antiepileptics [133, 134] and are also 
common for SSRIs and SNRIs [135]. Although there are no published articles addressing this issue, 
it is not surprising that there are increased risks for nausea if antiepileptics are combined with 
SSRIs or SNRIs. TCAs [136] and mirtazapine [137] have occasionally been used as antiemetics. 
Retigabine can cause urinary retention due to its interference with bladder voltage-
dependent potassium channels [138]. It should be very cautiously combined with antidepressants 
associated with urinary retention, including more potent antimuscarinic antidepressants (most 
TCAs, mirtazapine and paroxetine), reboxetine and SNRIs (Figure 4). 
 Less common PD DIs possibly associated with combinations of antiepileptics and 
antidepressants may include increased risk for lethal ADRs including hyponatremia, arrhythmias, 
hepatotoxicity, hemorrhages and heat stroke.  
Many antidepressants [139] and two antiepileptics [140], oxcarbazepine and carbamazepine, 
appear to be consistently associated with hyponatremia, probably mediated by increasing 
antidiuretic hormone (ADH) release and/or action. Clinical manifestations are relatively uncommon 
and are more frequent in elderly females [139].  Recent larger hyponatremia studies [141] did not 
explore the possibility that combinations of an antidepressant with one of these antiepileptics may 
be more prone to cause symptomatic hyponatremia that the individual drugs.  
 Lethal arrhythmias are very complicated to study since these deaths are relatively rare and 
are not easily identified in autopsies. Several syndromes are associated with sudden cardiac death. 
One of them is Brugada syndrome (see footnote 7 of Figure 3), which has been linked with newer 
antidepressants (Figure 5) and some antiepileptics (Figure 3) [142]. Obviously, the listed 
antiepileptics and antidepressants should be avoided in these patients and never combined.  
Several antidepressants have been associated with torsades de pointes including citalopram, 
fluoxetine and sertraline (Figure 5) [143, 144]. They should not be combined with felbamate, which 
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has also been associated with torsades de pointes, or with retigabine, which has been associated 
with QTc prolongations (Figure 3).     
Agomelatine has been definitively associated with liver enzyme elevations. Most cases 
(90%) recover after agomelatine discontinuation but severe forms can also occur [145]. 
Agomelatine should be very carefully prescribed when started in any patients using antiepileptics 
with greater risk of hepatotoxicity including carbamazepine, felbamate, phenytoin and valproate. In 
their recent review, Voican et al. [146] stated that, besides agomelatine, bupropion, duloxetine, 
TCAs and trazodone are the most frequent antidepressants that, on rare occasions, can cause life-
threatening hepatotoxicity. They suggest that these antidepressants should not be administered in 
those with prior liver problems. Therefore, we propose that bupropion, duloxetine, TCAs and 
trazodone should not be used in those with prior history of liver injury secondary to antiepileptics, 
or with current liver enzyme elevations during antiepileptic treatment.   
Figure 5 indicates that epidemiological studies definitively establish SSRIs as producing a 
small increased risk for abnormal bleeding by depleting platelets from serotonin, particularly when 
other risk factors are present, such as some drugs or surgery [147]. Valproate causes a common 
dose-related thrombocytopenia and on rare occasions interferes with the coagulation system [148; 
Figure 3] and may increase the risk of SSRI-induced bleeding, but this DI has not been studied. 
 Topiramate and zonisamide are inhibitors of carbonic anhydrase, decreasing the ability to 
produce sweat. Antimuscarinic drugs such as TCAs and mirtazapine can also cause hypohidrosis 
[149].  Combinations of topiramate or zonisamide with most potent antimuscarinic antidepressants 
should be avoided during hot summers, particularly in the elderly, or in patients exposed to 
strenuous exercise. 
Suicide and osteoporosis are two possible ADRs that have been associated with 
antiepileptics and antidepressants, but the connections are not definitively established due to the 
difficulty of studying them.  If these associations are not spurious, the combinations of these drugs 
may increase the risk.  
After meta-analyses, the US Food and Drug Administration (FDA) issued separate warnings 
of suicidality with antidepressants and antiepileptics. The risk of suicidality on antidepressants 
decreased and the benefits increased with age. There was a significant twofold risk of suicidality 
among children and adolescents randomized to antidepressants; whereas there was a statistically 
significant protective effect of antidepressants among those 65 and older [150]. Risk of suicidality, 
mainly suicidal ideation, was significantly elevated among subjects randomized to receive an 
antiepileptic, compared with placebo [151].  As these warnings come from studies in which it is not 
easy to eliminate confounders, including the presence of psychiatric disorders, the warnings are 
19 
considered controversial by many clinicians. The literature does not comment on the possibility of 
the increased risk of suicide in combining antiepileptics and antidepressants. Leon et al., [152] 
using a sophisticated statistical approach to analyze observational studies, concluded that the risk of 
suicide attempts or suicides was significantly reduced when the participants received 
antidepressants.  However, there was neither significant risk nor protection from suicidality among 
participants receiving antiepileptics. 
 Strong inducer antiepileptics are definitively associated with osteoporosis (Figure 1) and 
epidemiological studies [153] are starting to suggest that SSRIs may also be associated with 
increased risk for osteoporosis (Figure 4). Although it has not been studied, they may potentiate 
each other’s effects on osteoporosis.  
 
4. Conclusion  
 This section and Table 4 provide a summary of the most important practical DI information 
for clinicians. 
 
4.1 PK DIs and clinical implications 
Carbamazepine, phenobarbital, phenytoin and primidone are potent inducers that are likely 
to have clinically relevant effects on several antidepressant levels (Table 3). Adding any of these 
inducers (in the absence of other inducers) may be associated with a decrease in antidepressant 
plasma concentration that may be associated with lack of efficacy. The discontinuation of these 
inducers (when other inducers are not prescribed) may be associated with an increase in plasma 
antidepressant concentration that may be associated with ADRs. As antidepressant TDM may not 
be developed for some new antidepressants or clinicians may not have access to it in their clinical 
practices, Table 4 provides estimates for correction factors based on the limited available literature. 
A major problem is the absence of studies of the effect of potent inducers with agomelatine, 
desvenlafaxine, duloxetine, escitalopram, levomilnacipran, reboxetine, sertraline, venlafaxine, 
vilazodone, and vortioxetine.  Antidepressants mainly dependent for their metabolism on CYP3A4 
such as reboxetine or vilazodone may be particularly sensitive to induction. According to data from 
antipsychotics dependent on CYP3A4, they may require a correction factor of at least 5 [28]. 
The pharmacokinetic DIs associated with mild CYP3A4 inducers, such as clobazam, 
eslicarbazepine, oxcarbazepine, rufinamide and topiramate (Table 4), are not likely to be clinically 
relevant in most patients taking antidepressants, but it cannot be ruled out that in some unusual 
patients they may have clinical relevance. In that sense, clinicians may need to be watchful when 
using high doses of oxcarbazepine (≥ 1200 mg/day) or topiramate (≥ 400 mg/day), particularly with 
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antidepressants that require important dose corrections, when using potent inducers such as 
mirtazapine and TCAs, or those mainly metabolized by CYP3A4 such as reboxetine or vilazodone. 
Antidepressant DI studies should consider that valproic acid may not be an inhibitor of some 
metabolic enzymes, but a mild inducer of other metabolic enzymes or transporters, or behave both 
as a mild inducer and a competitive inhibitor [70].      
Fluoxetine and fluvoxamine are relevant inhibitors of phenytoin and valproic acid, but the 
literature does not provide information on calculating dose correction factors. Therefore, fluoxetine 
and fluvoxamine should not be added or discontinued from patients taking phenytoin or valproic 
acid without close monitoring of the antiepileptic TDM. Other not-well-studied antiepileptics likely 
to be influenced by the inhibitory effects of fluoxetine or fluvoxamine are those dependent on 
CYP2C9 or CYP2C19 for their metabolism, including clobazam, lacosamide, phenobarbital, or 
primidone. Fluoxetine may take up to 2-3 months in an average patient (or even up to 6 months in 
unusual patients) to reach maximal inhibitory effects on CYP3A4 due to the long half-life of 
norfluoxetine, so it may be important to remember that when co-prescribing fluoxetine with 
antiepileptics dependent on CYP3A4 such as carbamazepine, felbamate, tiagabine, or zonisamide. 
Table 4 reports that it may be safer to select antidepressants other than fluoxetine or fluvoxamine 
when taking any of these antiepileptics. Isolated cases have suggested that it may be safer to avoid 
fluoxetine and sertraline in patients taking lamotrigine (Table 4).  Studies of high doses of sertraline 
should rule out that it inhibits valproate and/or lamotrigine metabolism. In vitro studies suggest that 
TCAs (Table 2) are moderate CYP2C19 inhibitors; therefore, TCAs have potential for inhibiting 
the metabolism of some antiepileptics including lacosamide and clobazam’s main metabolite.    
 
4.2 PD DIs and clinical implications 
In our experience, pharmacodynamic DIs are very relevant in clinical practice (Table 4). 
Five unstudied pharmacodynamic DIs may prove beneficial by increasing efficacy (Table 4):  i) the 
possible additive effects for generalized anxiety disorder when adding pregabalin to an 
antidepressant, ii) the possible additive effects for chronic pain when combining some antiepileptics 
(carbamazepine, gabapentin, oxcarbazepine, or pregabalin) with SNRIs or TCAs, iii) the possible 
additive effects for migraine prophylaxis when combining topiramate or valproic acid with TCAs 
(particularly amitriptyline)  or venlafaxine, iv) the possible additive effects for weight control  when 
combining bupropion and zonisamide (or topiramate), and v) the possible additive effects for 
menopausal symptoms when combining gabapentin with SNRIs or SSRIs.   
Two pharmacodynamic DIs may cause harm by decreasing efficacy (Table 4): i) some 
antiepileptics, (Table 4) particularly phenobarbital, primidone, topiramate,  and vigabatrin have 
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been associated with depression and should be avoided in patients with that vulnerability; and ii) 
bupropion and TCAs should be avoided in patients with epilepsy due to the risk of decreasing the 
seizure threshold. The controversial issue of adding antidepressants for bipolar depression has been 
described in Section 3.2.2. 
Two unstudied PD DIs have the potential to be beneficial by increasing safety (Table 4): i) 
topiramate and zonisamide may decrease the effect on weight of antidepressants associated with 
weight gain (amitriptyline, mirtazapine, paroxetine), and ii) rufinamide may decrease QTc in 
patients with SSRIs. Fluoxetine has been associated with in vitro effects of anticonvulsant 
properties but has major potential for pharmacokinetic DIs. It is not clear whether other SSRIs share 
those anticonvulsant properties. Bupropion and TCAs clearly decrease the seizure threshold.   
 Five additive (or synergistic) DIs with increased risk for common ADRs include increased 
risk for sedation, weight gain, hyperlipidemia, nausea, and urinary retention. Table 4 describes the 
specific combinations, along with these increased safely risks. Finally, Table 4 describes five 
potentially lethal PD DIs: hyponatremia, torsades de pointes, hepatic failure, hemorrhages, and heat 
stroke. These ADRs are very rare and we are not sure that antiepileptic-antidepressant combinations 
increase their risk but pharmacological mechanisms suggest that possibility, and clinicians need to 
remember the potential for PD Dis in order to prevent or quickly diagnose them.  
Finally, long-term treatment with antiepileptics that are potent inducers is definitively 
associated with osteoporosis.  Recent studies, which may take many years for definitive 
confirmation, suggest that mild inducers, such as oxcarbazepine, topiramate or valproic acid, and 
SSRIs may be associated with osteoporosis. Clinicians may want to consider the possible increased 
risks when combining SSRIs with these mild inducers over many years.    
 
5. Expert opinion 
The pharmacological mechanisms and clinical relevance of DIs associated with the 
inductive properties of carbamazepine, phenytoin, phenobarbital and primidone and the inhibitory 
properties of valproate and some antidepressants are well understood while pharmacokinetic DI 
studies with new antiepileptics and new antidepressants are limited. It appears safer to overwarn 
clinicians about the potential risks of losing efficacy when adding inducers or of increased ADRs 
when adding inhibitors, as well as the risks of ADRs when discontinuing inducers or losing efficacy 
when discontinuing inhibitors. Clinicians cannot afford to wait for definitive studies, which are not 
likely to happen once the new drugs are already marketed.  Table 4 provides correction factors 
calculated using the available PK studies, assuming that the average patient represents the 
population well. However, there is extensive PK variability among patients, and TDM 
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measurements should be advised for optimal titration of the dosage in each individual. These 
limited correction factors are useful because:  i) many clinicians have no access to TDM; ii) there is 
limited clinical data on TDM for new compounds; and iii) having the correction factor helps 
clinicians to make decisions to use safer drugs. With a correction factor of 10, bupropion is a very 
poor antidepressant choice for patients taking antiepileptics with powerful inductive properties. 
There will be a need to periodically update these correction factors as new knowledge becomes 
available.  
 Using the limited available information, the authors believe that in high doses oxcarbazepine 
(≥ 1200 mg/day) and topiramate (≥ 400 mg/day) may be clinically relevant CYP3A4 inducers and 
possible inducers of some UGTs.  It is possible that clobazam, eslicarbazepine, and rufinamide may 
also be dose-dependent CYP3A4 inducers. Two other mild inducers, felbamate and vigabatrin, are 
rarely prescribed. More problematic is the case of valproic acid, a drug traditionally considered a 
potential inhibitor, which may also be a dose-dependent mild inducer of some antipsychotics.  The 
metabolic enzymes and/or transporters influenced by valproic acid induction are not known. These 
metabolic enzymes and/or transporters may also be subject to competitive inhibition by valproic 
acid [70]. As described earlier, valproic acid may also a vitamin D inducer [45].  
It is not easy to conduct DI studies using clinically relevant doses of inducers or inhibitors. 
Pharmaceutical companies tend to invest in simple PK DI studies in volunteers, frequently using 
single dosing to get approval for the marketing of their drugs, but this type of PK study rarely 
reflects clinical practice.  The DI material in prescribing information (or package inserts) is usually 
not designed to provide easy helps for clinicians to correct PK DIs with dose changes. It appears 
naïve to criticize the PK science on antiepileptic-antidepressant combinations; at least there is some 
PK data. There is almost no PD science on antiepileptic-antidepressant combinations. The potential 
PD DIs described in Table 4 were developed after reviewing known pharmacological mechanisms, 
efficacy and ADRs in antiepileptic or antidepressant studies. There are almost no studies of the 
potential synergistic or additive benefits of combining antiepileptics and antidepressants for 
generalized anxiety disorder, pain, migraine prophylaxis, weight and menopausal symptoms. The 
lack of studies in OCD is an even more problematic case. Some studies have used adjuvant 
antiepileptics such as lamotrigine for patients who did not sufficiently respond to SSRIs [121].  
OCD guidelines usually recommend SSRIs as first-line, followed by augmentation with 
clomipramine and/or antipsychotics, but there is no information for clinicians on what to do when 
all three treatments have been tried. Patients resistant to these three steps are usually very impaired 
and not likely to recover spontaneously, or have placebo response [154]. It would be ideal to 
complete RCTs with adjunctive treatment with lamotrigine or topiramate, but the great severity of 
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this type of treatment-refractory patients make them unlikely to take part in RCTs. This is a good 
example of a generalized problem in clinical practice:  the more difficult the patient, the less 
information is available to guide the treatment.  In difficult patients, clinicians frequently use drug 
combinations in the absence of good information on their risk/benefit; moreover, they prefer 
combinations to monotherapy.  
Clinicians use antiepileptic-antidepressant combinations frequently in patients for anxiety 
disorder, pain, migraine prophylaxis, weight and menopausal symptoms, looking for greater 
efficacy, and for depression in the presence of any primary indications for antiepileptics such as 
epilepsy.  There is obviously more need for studies of PK and PD DI between antiepileptics and 
antidepressants, but the lack of funding for clinical research is a major limitation. Collaboration 
from all interested parties is needed, including: i) drug agencies and pharmaceutical companies; ii) 
clinicians using antiepileptic-antidepressant combinations; iii) researchers with expertise in a) meta-
analyses, b) pharmacoepidemiology, and c) DI pharmacology; and iv) grant agencies.   
Drug agencies should be more insistent upon rapid approval for new antiepileptics with PD 
mechanisms analogous to those from already-approved compounds and with less risk for PK DIs. 
Oxcarbazepine and eslicarbazepine are likely to have efficacy in the same disorders as 
carbamazepine. It may be a good idea for drug agencies to facilitate and simplify an efficacy study 
as a long-term PK study with high doses and enough time duration to establish the real potential for 
induction of these compounds. There are analogs of valproic acid in development for epilepsy but it 
will be important to establish that they have better pharmacokinetic DIs and less toxicity than 
valproic acid for non-epileptic indications.  
There is great need for naturalistic studies by clinicians describing the possible additive or 
synergistic effects related to the efficacy and safety of the antiepileptic-antidepressant 
combinations. Are early sedation or early nausea and vomiting more frequent in some of these 
combinations than in the various monotherapies?  Is osteoporosis a long-term issue in vulnerable 
patients taking mild antiepileptic inducers and SSRIs for years? 
Researchers with expertise in meta-analysis may need to be ready to analyze the efficacy 
and safety of antiepileptic-antidepressant combinations, comparing them to studies of the drugs 
individually. Researchers with expertise in pharmacoepidemiology need to explore whether rare, 
but potentially lethal, ADRs such as hyponatremia, torsades de pointes, hepatic failure; 
hemorrhages, and heat stroke may be more frequently associated with using antiepileptic-
antidepressant combinations than with individual drugs. Researchers with expertise in in vitro DI 
studies or in vivo clinical studies using isotopes to explore drug clearance need to better study the 
new antiepileptics’ and the new antidepressants’ metabolic pathways and how they change when 
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inhibitors, such as valproic acid or SSRIs, and inducers, such as high doses of mild inducers, are 
added.  
Grant and health agencies need to remember that pragmatic clinical trials are key in treating 
complex disorders such as epilepsy, bipolar disorder, chronic pain or in preventing migraines where 
polytherapy is the norm. Pharmaceutical RCTs do not substitute for long-term pragmatic trials that 
may better inform clinicians of the effectiveness of the various types of mono- and polytherapy 
frequently used in the real world of clinical practice. Pragmatic trials need to pay better attention to 
DIs. 
Knowledge of DIs is becoming more complex, since even antiepileptic mild inducers may 
have clinically relevant PK DIs. Progress in the next few years may not be guaranteed even if this 
ambitious research agenda is followed, unless it is accompanied by a better continuous medical 
education concerning DIs and improvements in neuropsychopharmacology textbooks, so that 
clinicians begin to pay more attention to PD and PK DIs associated with the frequent co-
prescription of antiepileptic-antidepressant combinations.  The authors would like to see well-
educated clinicians assist in pushing this research agenda forward by publishing DI case reports of 
unusual combinations and asking for more DI studies from pharmaceutical companies and 
researchers. 
25 
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Table 1. Pharmacokinetic parameters of antiepileptics. Based on [28, 37]. 
 
 
 Bioavail
-ability 
(%) 
Protein 
binding 
(%) 
Half-
life (h) 
Most important 
way of 
elimination1 
Other ways of elimination Active metabolites Induction or 
inhibition of 
metabolic enzymes 
FIRST GENERATION  
Carbamazepine 75-85 75 5-26 CYP3A42 CYP2C8, CYP1A2, 
UGT2B7, epoxide hydrolase 
Carbamazepine 
epoxide 
Induction of CYP1A2, 
CYP2A6, CYP2B6, 
CYP2C9, CYP2C19, 
CYP3A4, UGT1A1, 
UGT2B7, UGT2B15,  
epoxide hydrolase  
Ethosuximide 90-100 <10 25-70 CYP3A42 CYP2E1, renal   
Phenytoin 90 90 7-80 CYP2C92 CYP2C19 (less important: 
CYP2C18, CYP3A4) 
 Induction of CYP1A2, 
CYP2B6, CYP2C8, 
CYP2C9,  CYP2C19, 
CYP3A4, UGTs, 
epoxide hydrolase 
Phenobarbital >95 45-60 70-130 CYP2C92 CYP2C19,  CYP2E1,  
N-glucosidation, renal  
 Induction of CYP1A2, 
CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, 
CYP2E1, CYP3A4, 
UGT, epoxide 
hydrolase 
Primidone >90 10 5-20 CYP2C92 Renal, CYP2C19,  CYP2E1,   
N-glucosidation, 
Phenobarbital Induction of CYP1A2, 
CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, 
CYP2E1, CYP3A4, 
UGT, epoxide 
hydrolase 
Valproate >90 70-95 8-16 Several UGTs -oxidation, CYP2C9 (other 
CYPs are minor)  
 Inhibition of CYP2C9, 
UGT1A4, UGT2B7, 
epoxide hydrolase, N-
glucosidation.  
 
38 
Mild auto-induction3
and mild induction of 
other drugs3 
SECOND GENERATION  
Clobazam 100 80-90 36-42 CYP3A42 CYP2C194 N-
desmethylclobazam 
Mild induction of 
CYP3A4 
 
Mild inhibition of 
CYP2C19 and 
CYP2D6 
Eslicarbazepine 100 30 13-20 UGTs5 Renal S-licarbazepine Mild induction of 
CYP3A4, UGTs. 
 
Mild inhibition  of 
CYP2C9, CYP2C19 
Felbamate 90 20-25 11-25 CYP3A42 Renal, CYP2E1, UGTs   Mild induction of 
CYP3A4 
 
Inhibition of 
CYP2C19, -
oxidation 
Gabapentin <65 0 5-9 Renal    
Lacosamide 100 <15 12-16 CYP2C192 Renal   
Lamotrigine >95 55 25 UGT1A4   Mild induction of 
UGTs. 
Levetiracetam  100 <10 6-8 Renal  Esterase hydrolysis in blood   
Oxcarbazepine  100 40 7-12 Renal UGTs MHD 
(monohydroxy 
derivate) 6  
Mild induction of 
CYP3A4, UGTs 
 
Mild inhibition of 
CYP2C19. 
Pregabalin >90 0 5-7 Renal    
Retigabine  
(ezogabine) 
60 80 8-10 Arylamine N-
acetyl 
transferase-2  
UGTs   
Rufinamide 85 30 8-12 Carboxyles-
terases
  Mild induction of 
CYP3A4, UGTs
39 
Mild inhibition of 
CYP2E1. 
Stiripentol >70 99 4.5-13  CYP1A2, CYP2C19, 
CYP3A4, UGTs7 
 Inhibition of CYP1A2, 
CYP2C19, CYP2D6, 
CYP3A4. 
Tiagabine 100 96 5-9 CYP3A42    
Topiramate 100 13-17 10-30 Renal CYP   Mild induction of 
CYP3A4, -oxidation, 
UGT1A4. 
 
Mild inhibition of 
CYP2C19. 
Vigabatrin >50 0 4-7 Renal CYP (only 10%)  Mild induction of 
CYP2C9. 
Zonisamide 100 50 50-70 CYP3A42 N-acetylation transferase, 
renal 
  
CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyltransferase 
1This refers to normal metabolism. Some subjects may not have this enzyme or have it inhibited. Other enzymes may become more important during induction.   
2Any substrate competes with others for the corresponding enzyme and inhibits it (competitive inhibition). There is data in the literature that competitive 
inhibition may occur at CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. UGTs tend to have overlapping substrates and it is not clear that they can be 
subject to competitive inhibition. A good example of competitive inhibition is phenytoin in high serum concentrations (>20 mcg/ml) which may saturate 
completely or almost completely its metabolic enzymes, CYP2C9 and CYP2C19.   
3Valproate has been demonstrated to have mild-autoinduction properties by inducing β-oxidation. Valproate may be an inducer of the metabolism of other 
medications including aripiprazole, clozapine, irinotecan and olanzapine but the induced enzymes are not established.  
4N-desmethlyclobazam is mainly metabolized by CYP2C19. 
5Eslicarbazepine is a pro-drug that is activated by hepatic esterases to S-licarbazepine. S-licarbazepine is eliminated by UGTs and by the kidney (unchanged).  
6MHD is also called licarbazepine. Oxcarbazepine is a pro-drug and is activated by a cytosolic arylketone reductase that converts it to MHD, the active drug.  
7There are four metabolic pathways. No specific enzyme can be considered a major enzyme.  
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Table 2. Pharmacokinetic parameters of antidepressants. Based on [29, 31-33, 39]. 
 
 
 Bioavail-
ability 
(%) 
Protein 
binding 
(%) 
Half-life (h) Most 
important way 
of elimination1 
 Other ways of 
elimination 
Active metabolites Inhibitory effect on CYP 
isoenzymes  
 
TCA       
Amitriptyline 30-60 96 10-50 CYP2C19 and 
CYP2D62 
CYP1A2, CYP2C9, 
CYP3A4 
Nortriptyline CYP2C19 (moderate) 
CYP2D6 (weak) 
Clomipramine 50 97-98 19-37 CYP2C19 and 
CYP2D62 
CYP1A2, CYP2C9, 
CYP3A4 
Desmethylclomipramine CYP2C19 (moderate) 
CYP2D6 (weak)  
Imipramine 43 60-95 8-20 CYP2C19 and 
CYP2D62 
CYP1A2, CYP2C9, 
CYP3A4 
Desipramine CYP2C19 (moderate) 
CYP2D6 (weak) 
Nortriptyline 51 93 16-38 CYP2D62   CYP2D6 (weak) 
SSRI   
Citalopram 95 82 23-45 CYP2C192  CYP3A4, CYP2D6  CYP2D6 (weak) 
Escitalopram 80 56 27 CYP2C192 CYP3A4, CYP2D6  CYP2D6 (weak) 
Fluoxetine 80 95 2-4 days CYP2D62 CYP2C9, CYP2C19, 
CYP3A4 
Norfluoxetine CYP2D6 (potent) 
CYP2C9 (moderate) 
CYP2C19 and CYP3A4 
(weak to moderate) 
CYP1A2 (weak) 
Fluvoxamine <53 77 15-22 CYP1A2, 
CYP2D6 
  CYP1A2 and CYP2C19 
(potent) 
CYP2C9 and CYP3A4 
(moderate) 
CYP2D6 (weak) 
Paroxetine >64 93 10-21 CYP2D62 CYP3A4  CYP2D6 (potent) 
CYP1A2, CYP2C9, 
CYP2C19, CYP3A4 (weak) 
Sertraline >44 98 22-36 CYP2B6 CYP2C19, CYP2C9, 
CYP2D6, CYP3A4 
 CYP2D6 (weak to 
moderate) 
CYP1A2, CYP2C9, 
CYP2C19 and CYP3A4 
(weak) 
SNRI       
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Desvenlafaxine 80 30 9-15 Renal UGT, CYP3A4   
Duloxetine 50 >90 10-12 CYP1A22 CYP2D6  CYP2D6 (moderate) 
Levomilnacipran 92 22 12 
 
Renal UGT, CYP3A4   
Milnacipran 85 13 8-10 Renal UGT, CYP3A4  CYP3A4 (weak) 
Venlafaxine 92 27 5 CYP2D62 CYP3A4 Desvenlafaxine  
Other newer 
antidepressants 
      
Agomelatine <5 95 1-2 CYP1A22 CYP2C9   
Bupropion 90 84 20 CYP2B6  Hydroxybupropion 
Threohydrobupropion 
Erythrohydrobupropion 
CYP2D6 (moderate) 
Mirtazapine 50 85 20-40 CYP2D6, 
CYP3A4 
CYP1A2, UGTs   
Reboxetine >60 97 12-16 CYP3A42    
Trazodone 65 89-95 5-9 CYP3A42  m-
chlorophenylpiperazine 
(mCPP) 
 
Vilazodone 723 96-99 20-24 CYP3A42 CYP2C19, CYP2D6, 
Carboxylesterase 
 
 
CYP2C8 (?) 
Vortioxetine 75 98 57-66 CYP2D62 CYP3A4, CYP2C19, 
CYP2C9, CYP2A6, 
CYP2C8, CYP2B6 
  
CYP: Cytochrome P450; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor; TCA; tricyclic  
antidepressant; UGT: Uridine diphosphate glucuronosyltransferase.  
1This refers to normal metabolism. Some subjects may not have this enzyme or the enzyme is inhibited. Other enzymes may become more important during 
induction. 
2 Any substrate competes with others for the corresponding enzyme and inhibits it (competitive inhibition). Data in the literature shows that competitive inhibition 
may occur at CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. UGTs tend to have overlapping substrates and it is not clear that they can be subject to 
competitive inhibition. For example, venlafaxine can behave as a CYP2D6 competitive inhibitor.  
3Absorption is decreased when not administered with food. 
 
 
 
42 
Table 3. Summary of pharmacokinetic drug interactions between antiepileptics and antidepressants.  
Antiepileptic Antidepressant Effect Proposed mechanism 
 
References 
Carbamazepine 
 
 
TCA Decrease in plasma TCA concentrations (40-70%)  
 
Induction of various CYP 
isoforms (CYP2C19, 
CYP1A2 and CYP3A4)  
[34] 
 Fluoxetine Minimal increase or no change in plasma concentrations of 
carbamazepine 
Inhibition of CYP3A4 (?) [89-91] 
 Paroxetine Decrease by 25% in plasma concentrations of paroxetine Induction of CYP (?) [60, 61] 
 Fluvoxamine Minimal increase or no change in plasma concentrations of 
carbamazepine  
Inhibition of CYP3A4 (?) [91, 96, 97] 
 Sertraline Marked decrease in plasma sertraline concentrations in two patients  Induction of CYP3A4 [62] 
 Citalopram Decrease in plasma concentrations of S-citalopram and R-citalopram 
by 27 and 31%  
Induction of CYP3A4          [63] 
 Milnacipran Decrease by 20% in plasma concentrations of milnacipran Induction of CYP3A4 and 
UGT 
[64] 
 Mirtazapine Reduction by 39% in Cmax of mirtazapine and by 66% in its AUC Induction of CYP3A4 [65]
 Bupropion Decrease in the Cmax of bupropion  by 87% and in its AUC by 90%  Induction of CYP3A4 [67] 
Phenobarbital 
 
TCAs Decrease in plasma TCA concentrations (40-70%)  
  
Induction of various CYP 
isoforms (CYP2C19, 
CYP1A2 and CYP3A4)  
[34] 
Phenytoin TCAs 
 
Decrease in TCA plasma concentrations (40-70%)  
 
Induction of various CYP 
isoforms (CYP2C19, 
CYP1A2 and CYP3A4) 
[34] 
 Fluoxetine Increase in plasma concentrations of phenytoin Inhibition of CYP2C9 [88] 
 Fluvoxamine A case report documented a 3-fold increase in serum concentrations of 
phenytoin after administration of fluvoxamine  
Inhibition of both CYP2C9 
and CYP2C19  
[98]
 Mirtazapine Reduction by 33% in Cmax of mirtazapine and by 47% in its AUC Induction of CYP3A4 [66] 
Valproic acid Amitriptyline  50% to 60% elevation in plasma concentrations of amitriptyline and 
nortriptyline  
Inhibition of CYP2C9 and, 
possibly CYP2C19 and 
CYP3A4 
   [71-73, 79]  
 Doxepin Higher serum concentrations of doxepin plus N-doxepin (by 124%, 
p<0.01) in patients comedicated with valproic acid 
Inhibition of CYP2C9 and, 
possibly CYP2C19 and 
CYP3A4 
[80] 
 Fluoxetine Increase in plasma concentrations of valproate Inhibition of CYP2C9 [92-94] 
 Venlafaxine Serum concentrations of the active metabolite O-
desmethylvenlafaxine were significantly higher (by 27%, p<0.02) in 
Inhibition of CYP2C9          [80] 
43 
patients treated with the combination of valproic acid with 
venlafaxine. 
Lamotrigine Fluoxetine Lower serum concentrations of lamotrigine in patients comedicated 
with fluoxetine 
Induction of UGT enzymes? 
 
       [99] 
 Sertraline 
 
Slight increase (by 18%) in plasma concentrations of lamotrigine Inhibition of UGT2B7?        [103] 
Cmax: Peak plasma concentration; AUC: Area under the plasma concentration-time curve; CYP: Cytochrome P450; TCA: tricyclic antidepressant. UGT: Uridine 
diphosphate glucuronosyltransferase.  
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Table 4. Practical summary of antiepileptic and antidepressant drug interactions       
ANTIEPILEPTICS  ANTIDEPRESSANTS OUTCOME ACTIONS
PK DI. Powerful inducers:     
carbamazepine, phenobarbital 
phenytoin, primidone 
↓ antidepressant level 2-4 wks after  
       adding inducer 
↑ antidepressant level 2-4 wks after D/C  
   Inducer 
In the absence of TDM, use correction factor:1   
Bupropion>2 Better to avoid unless having extensive bupropion 
TDM experience3 
Mirtazapine> 2-3 
TCAs>2 2 (1.4-2,5)4 Better using TCA TDM 
Citalopram, milnacipran, paroxetine 1.3 If this correction factor is correct, it may not be 
clinically relevant 
Agomelatine, desvenlafaxine, 
duloxetine, escitalopram, 
levomilnacipran, reboxetine, 
sertraline, venlafaxine, vilazodone, 
vortioxetine 
Not studied  
Be careful; induction of these antidepressants is 
possible. Reboxetine and vilazodone (dependent on 
CYP3A4 for their metabolism) may require high 
correction factors: ≥5)  
Fluoxetine, fluvoxamine Not relevant Possibly no clinically relevant changes 
PK DI. Mild CYP3A4 
inducers:3  
Clobazam, eslicarbazepine, 
felbamate, oxcarbazepine, 
topiramate,  
Rufinamide 
Possibly relevant for: bupropion, 
mirtazapine, TCAs, reboxetine, 
vilazodone 
↓ mild antidepressant level 2-4 wks after  
       adding mild inducer 
↑ mild antidepressant level 2-4 wks after  
      D/C  mild inducer  
Monitor for ↓ efficacy after adding mild inducer. 
Monitor for ADRs after discontinuing mild inducer 
PK DI. Phenytoin, valproate Fluoxetine, fluvoxamine ↑ antiepileptic level after adding inhibitor 
↓ antiepileptic  level after D/C inhibitor 
Use antiepileptic TDM 
It may be safer to select another antidepressant Not studied but likely to be 
relevant: clobazam, 
lacosamide, phenobarbital, or 
primidone.  
Not studied at steady state; 
inhibitory effects of 
fluoxetine: carbamazepine, 
felbamate, tiagabine, 
zonisamide 
Fluoxetine ↑ antiepileptic level  2-3 months after  
adding fluoxetine in average patient (some 
may take longer) 
↓ antiepileptic level 2-3 months after  
adding fluoxetine in average patient (some 
may take longer) 
Use antiepileptic TDM 
It may be safer to select another antidepressant 
PK DI. Valproate TCAs  ↑ TCA level after adding valproate  
↓ TCA  level after D/C valproate 
Better using TCA TDM 
Monitor for TCA ADRs 
PK DI. Lamotrigine Fluoxetine, sertraline Some isolated cases suggest that 
lamotrigine induction may be possible with 
fluoxetine and lamotrigine inhibition may 
Be alert to the possibility that fluoxetine may ↓ 
lamotrigine levels while sertraline may ↑ 
lamotrigine level 
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be possible with sertraline. Consider lamotrigine TDM before and after adding 
fluoxetine or sertraline or select another 
antidepressant 
PD DI. Pregabalin Antidepressants May have additive effects for generalized 
anxiety disorder (not well-studied) 
Be aware 
PD DI. Carbamazepine, 
gabapentin, oxcarbazepine, 
pregabalin 
SNRIs, TCAs May have additive effects for pain treatment 
(not well-studied) 
Be aware 
PD DI. Topiramate, valproic 
acid 
TCAs, particularly amitriptyline. 
Possibly venlafaxine 
May have additive effects for migraine 
treatment (not well-studied) 
Be aware 
Remember that valproic acid may ↑ TCA level  
PD DI. Zonisamide (possibly 
topiramate) 
Bupropion  May have additive effects for weight 
reduction (not well-studied) 
Be aware 
PD DI. Gabapentin SNRIs, SSRIs  May have additive effects for reducing 
menopausal symptoms (not well-studied;  
none of these drugs have been approved) 
Be aware 
PD DI. Phenobarbital, 
primidone, topiramate,  
vigabatrin> zonisamide > 
felbamate, levetiracetam, 
tiagabine 
Antidepressants These antiepileptics have been associated 
with depression 
Avoid using them in patients taking antidepressants 
for depression 
If you use them, review PK DIs 
PD DI. Antiepileptics for 
epilepsy 
Bupropion, TCAs These antidepressants  have been associated 
with ↑ risk for seizures 
Avoid using them in patients taking antiepileptics 
for epilepsy 
If you use them, review PK DIs 
PD DI. Antiepileptics for 
epilepsy 
Fluoxetine (possible other SSRIs and 
SNRIs) 
Fluoxetine has displayed in vitro 
antiepileptic properties in some models 
Other SSRIs and SNRIs  have been 
associated with ↓ risk for seizures in meta-
analyses but there are also case reports 
associating  them with seizures in patients 
with no seizure history 
Consider them when needing antidepressant in 
patients taking antiepileptics for not-well-controlled 
epilepsy 
If you decide to use fluoxetine, be very careful with 
PK DIs 
PD DI. Topiramate, 
zonisamide 
Amitriptyline, mirtazapine, paroxetine These antiepileptics have been associated 
with ↓ weight gain 
Be aware  
If you use them, review other PK and PD DIs 
PD DI. Rufinamide SSRIs Rufinamide has been associated with ↓ in 
QTc 
Be aware  
If you use them, review other PK and PD DIs 
PD DI. Most antiepileptics  Mirtazapine, TCAs, and trazodone Additive sedation risk Be aware  
Remember that felbamate, lacosamide, lamotrigine 
and tiagabine are less sedating 
PD DI. Carbamazepine, 
gabapentin, pregabalin, 
retigabine, valproate 
Amitriptyline, mirtazapine, paroxetine These antiepileptics and antidepressants 
have been associated with ↑ weight gain and 
may have additive effects. 
Be aware  
 
PD DI. Carbamazepine, Mirtazapine These antiepileptics and mirtazapine have Be aware  
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phenobarbital, phenytoin, 
primidone 
been associated with hyperlipidemia and 
may have additive effects 
If you use them, review other PK and PD DIs 
PD DI. Most antiepileptics  SNRIs, SSRIs Most antiepileptics and these 
antidepressants have been associated with 
nausea/vomiting and may have additive 
effects 
Be aware  
If you use them, review other PK and PD DIs 
Mirtazapine and TCAs may have less risk for 
nausea and may have anti-nausea effects in some 
patients 
PD DI. Retigabine Most TCAs>2 mirtazapine, paroxetine 
due to antimuscarinic activity; 
SNRIs and reboxetine probably due to 
noradrenergic mechanisms 
Retigabine and these antidepressants have 
been associated with ↑ risk for urinary 
retention  
Be aware if you combine them 
 
PD DI. Oxcarbazepine>2 
carbamazepine 
Probably all antidepressants Oxcarbazepine and carbamazepine and 
antidepressants have been associated with ↑ 
risk for hyponatremia  
Be particularly careful in geriatric females who 
have more risk of developing hyponatremia. 
Polydipsic patients with severe mental illness may  
have hyponatremia risk with only one of these 
drugs  
PD DI. Felbamate, retigabine SSRIs (particularly citalopram, 
fluoxetine and sertraline) 
 
Possible additive risk for ↑ QTc Be vigilant (can be lethal) 
Consider need for ECG 
Torsades de pointes is very rare but additive risk 
factors are family history of sudden death; personal 
history of syncopes, arrhythmias or heart cond- 
itions; hypokalemia, hypomagnesemia, and co-
prescription of other medications that ↑ QTc. Cases 
are more frequent in females aged > 65 years 
In the US, consider legal risk. The FDA requires a 
QTc warning for the use of high doses of 
citalopram 
Consider these warnings when co-prescribing 
PD DI. Carbamazepine, 
felbamate, phenytoin, 
valproate 
Agomelatine Possible additive risk for hepatic injury Be extremely  careful when adding agomelatine to 
these antiepileptics and consider other 
antidepressants  
PD DI. Carbamazepine, 
felbamate, phenytoin, 
valproate 
Bupropion, duloxetine, TCAs and 
trazodone 
Possible additive risk for hepatic injury Be very careful when adding these antidepressants 
and antiepileptics; consider other alternatives and 
monitor liver enzymes 
These antidepressants should not be used in those 
with prior history of liver injury secondary to 
antiepileptics, or with current liver enzyme 
elevations during antiepileptic treatment   
PD DI. Valproate SSRIs Possible additive hemorrhagic risk Monitor closely if you decide to co-prescribe  
PD DI. Topiramate, 
zonisamide rarely 
TCAs and mirtazapine due to 
antimuscarinic activity   
Both may be associated with heat stroke  In elderly and/or exposed to strenuous exercise or 
high temperatures:  
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Be vigilant (can be lethal). Encourage proper 
hydration    
PD DI.  Carbamazepine, 
phenobarbital, phenytoin,  
primidone >2 oxcarbazepine, 
topiramate, valproate 
SSRIs Possible additive osteoporosis risk Monitor closely if you decide to co-prescribe  
ADR: adverse drug reaction; PD DI: pharmacodynamic drug interaction; PK DI: pharmacokinetic drug interaction; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI: 
Selective serotonin reuptake inhibitor.    
1Reviewed PK DI studies were used to estimate correction factors, which are >1 in inducers and <1 in inhibitors. A correction factor of 2 indicates that you need to double the 
dose for the same effect. A correction factor of 0.5 indicates that you need to halve the dose for the same effect. The further the correction factor is from 1, the more relevant the 
DI may be. The therapeutic window or index also determines the clinical relevance of correction factors. 
 2Drugs preceding ">" will produce a more powerful outcome than the drugs listed on the following line. 
3The bupropion correction factor is 10. It is so large that it appears better to avoid bupropion unless TDM is available.  
4The correction factor of 2 for TCAs is based on a decrease of 50% of plasma concentrations. As Table 3 shows, the decreases may range from 40% to 70%; this will provide a 
correction factor ranging from 2.5 to 1.4. It is better to use TDM than correction factors to correct the dose in each patient more accurately.   
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PHARMACOKINETICS OF ANTIEPILEPTICS FOR ENDOGENOUS 
COMPOUNDS INFLUENCING SAFETY 
OSTEOPOROSIS (after many years of treatment, making it difficult to establish frequencies) 
Induction of Vitamin D metabolism 
Carbamazepine, phenobarbital, phenytoin, primidone >1 oxcarbazepine, topiramate, valproate 
THYROID DISTURBANCES (relatively uncommon) 
Induction of thyroid hormone metabolism 
Carbamazepine, phenytoin2 
HYPERLIPIDEMIAS (there are no long-term prospective studies) 
Induction of enzymes important for lipid metabolism 
Carbamazepine, phenobarbital, phenytoin, primidone3 
SEXUAL DISTURBANCES (clinical relevance is unclear) 
Induction of sexual hormone metabolism4 
Carbamazepine, phenobarbital, phenytoin 
HYPERHOMOCYSTINEMIA (possible risk factor for atherosclerosis) 
Disturbances of folic acid and vitamin B12 metabolism5 
Carbamazepine, phenobarbital, phenytoin, primidone >1 oxcarbazepine, topiramate, valproate 
Figure 1. Pharmacokinetics of antiepileptics for endogenous compounds influencing safety.  
1Drugs preceding ">" will produce this ADR more frequently than drugs following ">". 
2Oxcarbazepine may be associated with mild thyroid disturbances. 
3Valproate appears to decrease total and high-density lipoprotein (HDL) cholesterol by unknown 
mechanisms. 
4Carbamazepine, phenobarbital and phenytoin may be associated with ↑increases in serum sex 
hormone-binding globulin concentrations in both men and women. Over time, the ↑ increase in 
serum sex hormone-binding globulin levels leads to ↓ testosterone and estradiol activity, which may 
result in diminished potency in men and menstrual disorders in some women. Valproic acid 
medication may have effects on serum androgen concentrations and it ↓ reduces serum follicle 
stimulating hormone levels in men; clinical relevance is unknown. In fertile women with epilepsy, 
there is more agreement that valproic acid may have clinical relevance and be associated with 
polycystic changes in the ovaries, high serum testosterone concentrations (hyperandrogenism) and 
menstrual disorders. These disorders are especially common among epileptic women who have 
gained weight during valproic acid treatment. It is not established whether these changes occur in 
non-epileptic women taking valproic acid for years. 
5Other abnormalities associated with folic acid deficits are gingival overgrowth associated with 
phenytoin treatment and poor oral hygiene, and macrocytic anemia associated with phenytoin and 
phenobarbital. It is believed that phenytoin may inhibit the folic acid transporter.   
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PHARMACODYNAMICS FOR ANTIEPILEPTIC EFFICACY 
ANTIEPILEPTIC ACTIVITY1
↓ Activity of voltage-dependent sodium channels 
Carbamazepine, eslicarbazepine, felbamate, lacosamide, lamotrigine, oxcarbazepine, phenytoin, rufinamide, topiramate, 
zonisamide 
↓ Activity of voltage-dependent calcium channels 
Ethosuximide, gabapentin, lamotrigine, pregabalin, topiramate, zonisamide 
↑ GABA neurotransmission 
Clobazam, felbamate, gabapentin, phenobarbital, pregabalin, primidone, stiripentol, tiagabine, topiramate, vigabatrin  
Complex including ↑ GABA neurotransmission 
Valproate 
↓ Glutamatergic neurotransmission 
Felbamate, topiramate 
Complex: binds to synaptic vesicle protein 2A (↓ synaptic vesicle recycling and NT release) 
Levetiracetam 
Allosteric modulator which enhances the activity of the slow voltage-gated potassium channels 
Retigabine 
MOOD STABILIZER ACTIVITY2 
At intracellular signaling system (inositol signaling) 
Carbamazepine, valproate 
Unknown mechanism 
Lamotrigine 
ANXIOLYTIC ACTIVITY 
↑ GABA neurotransmission 
Clobazam, pregabalin (off-label in the US)3 
FOR PAIN4 
↓ Activity of voltage-dependent sodium or calcium channels 
Carbamazepine, gabapentin, oxcarbazepine, pregabalin 
FOR MIGRAINE PROPHYLAXIS5 
Unknown mechanism 
Topiramate, valproate
↓ APPETITE AND WEGHT LOSS (off-label in the US)6 
Inhibition of carbonic anhydrase 
Topiramate, zonisamide 
MENOPAUSAL VASOMOTOR SYMPTOMS (HOT FLASHES & NIGHT SWEATS) 
Unknown mechanism 
Gabapentin (off-label in the US) 
Figure 2. Pharmacodynamics for antiepileptic efficacy. 
This figure is an update from Figure 2 in a prior article [28].   
1Different articles describe different mechanisms of action for some drugs including levetiracetam, 
valproate and zonisamide. 
2Antiepileptics approved in the US for bipolar disorder include: i) valproate for mania; ii) 
carbamazepine for the treatment of acute manic and mixed episodes of bipolar disorder; and iii) 
lamotrigine for prophylaxis, particularly of depressive phases. Treatment guidelines also consider: 
i) valproate monotherapy or adjunctive therapy for bipolar depression or prophylaxis, ii) 
carbamazepine monotherapy or adjunctive therapy for prophylaxis, and iii) lamotrigine 
monotherapy or adjunctive therapy for bipolar depression. Gabapentin, lamotrigine and topiramate 
mania RCTs were negative. Oxcarbazepine bipolar disorder RCTs appear promising. There are no 
published RCTs for eslicarbazepine, levetiracetam or zonisamide. 
3Pregabalin is approved for generalized anxiety disorder in Europe but not in the US. Clobazam has 
not been approved for anxiety in the US but has been widely used as an anxiolytic in other 
countries. Other antiepileptics may have antianxiety properties. 
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4In the US approved drugs include: i) carbamazepine for trigeminal neuralgia, ii) gabapentin for 
postherpetic neuralgia, and iii) pregabalin for postherpetic neuralgia and diabetic neuropathic pain. 
Lacosamide is being studied in RCTs for diabetic neuropathic pain. Oxcarbazepine is usually 
considered an alternative for trigeminal neuralgia when patients cannot tolerate carbamazepine. 
Other antiepileptics, including levetiracetam, lamotrigine and phenytoin are considered by some 
authors as acceptable treatments for neuropathic pain. 
5In the US, the only antiepileptics approved for migraine prophylaxis are topiramate and valproate.   
6Topiramate and zonisamide treatments are frequently associated with weight loss. In the US, the 
combination of topiramate and phentermine (a sympathomimetic amine anorectic agent) has been 
approved as an adjunctive treatment to a reduced-calorie diet and increased physical activity for 
chronic weight management in obesity or overweight with complications. 
NT; neurotransmitter; RTC: randomized clinical trial.  
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PHARMACODYNAMICS FOR ANTIEPILEPTIC SAFETY 
SEDATION (common) 
Same mechanism that explains antiepileptic efficacy 
FGAED and topiramate >1 other SGAEDs >1 felbamate, lacosamide, lamotrigine, tiagabine 
COGNITIVE IMPAIRMENT(common) 
Same mechanism that explains antiepileptic efficacy 
Definitively in FGAEDs and probably in SGAEDs2 
BALANCE DISTURBANCES AND/OR MOTOR OCULAR3 ADRs (common)  
Same mechanisms that explain antiepileptic efficacy 
Most AEDS 
DEPRESSION4
 ↑ GABA neurotransmission 
Phenobarbital, primidone, topiramate, vigabatrin (common) >1 zonisamide >1 felbamate, levetiracetam, tiagabine 
VISUAL FIELD DEFECTS 
Retinal accumulation of GABA 
Vigabatrin (common) > rare in topiramate 
WEIGHT GAIN (common in long-term treatment) 
Unknown mechanism 
Carbamazepine, gabapentin, pregabalin, retigabine, valproate 
NAUSEA AND VOMITING (common) 
↓ activity of voltage-dependent sodium channels 
Carbamazepine, eslicarbazepine, felbamate, lacosamide, lamotrigine, oxcarbazepine, phenytoin, rufinamide, topiramate, 
zonisamide 
Unknown mechanism 
Ethosuximide, levetiracetam, phenobarbital, tiagabine, valproate 
HYPONATREMIA 
SIADH and/or increase in ADH sensitivity 
Oxcarbazepine (common) >1 carbamazepine >1 rare in other AEDs 
COAGULATION IMPAIRMENT 
Thrombocytopenia (mediated by toxic mechanisms) 
Valproate (common and dose-related) >1 pregabalin 
Interference with coagulation factors 
Valproate (relatively uncommon)
PARADOXICAL SEIZURES (relatively uncommon) 
Same mechanism that explains antiepileptic efficacy 
Carbamazepine, tiagabine >1 other AEDs >1 valproate 
ABUSE (relatively uncommon) 
Same mechanism that explains antiepileptic efficacy 
Clobazam, phenobarbital > lacosamide, pregabalin, retigabine > gabapentin  
PSYCHOSIS (relatively uncommon)5
Unknown mechanism 
Ethosuximide, levetiracetam, lamotrigine, retigabine, tiagabine, topiramate, vigabatrin, zonisamide 
AGGRESSIVE  BEHAVIOR (relatively uncommon)6 
Unknown mechanism 
Gabapentin, levetiracetam, lamotrigine, phenobarbital, topiramate, vigabatrin, zonisamide 
HYPERAMMONEMIC ENCEPHALOPATHY (relatively uncommon) 
Interference with urea cycle 
Valproate 
MOVEMENT DISORDERS (relatively uncommon) 
Unknown mechanisms which vary according to type of movement disorder 
Many AEDs 
METABOLIC ACIDOSIS/UROLITHIASIS (relatively uncommon) 
Inhibition of carbonic anhydrase 
Topiramate, zonisamide 
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↓ BLADDER CONTRACTILITY AND URINARY RETENTION (relatively uncommon) 
↑Activity of bladder voltage-dependent potassium channels 
Retigabine 
LEUKOPENIA (relatively uncommon) 
Unknown mechanism 
Carbamazepine, ethosuximide, felbamate, phenobarbital, primidone, valproate 
PR INTERVAL PROLONGATION (relatively uncommon) 
↓ Activity of cardiac voltage-dependent sodium channels 
Carbamazepine, lacosamide > lamotrigine, pregabalin
SUDDEN CARDIAC DEATH ASSOCIATED WITH ARRYTHMIAS 
Antagonism of heart channels 
QTc prolongation (relatively uncommon) 
Retigabine 
Torsades de pointes (very rare)6  
Felbamate  
Antagonism of heart sodium, potassium or calcium channel 
Risk for patients with Brugada syndrome7  
 Avoid: oxcarbazepine. Preferably avoid: carbamazepine, lamotrigine, phenytoin 
STEVENS–JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS  
(very rare: 1-10/10,000-100,000) 
Immunological mechanisms 
Definitive: carbamazepine, ethosuximide, felbamate, lamotrigine, phenobarbital, phenytoin, primidone 
Less well-established: oxcarbazepine, valproate, zonisamide  
AGRANULOCYTOSIS AND/OR APLASTIC ANEMIA(very rare: 1-10/10,000-100,000)
Immunological mechanisms 
Carbamazepine, ethosuximide, felbamate, phenobarbital, primidone, valproate 
LIVER INJURY 
Unknown mechanism 
Liver enzyme elevations (common) 
Most AEDs 
Immune-allergic or toxic by metabolites 
Life-threatening liver injury (rare)  
Carbamazepine, felbamate, phenytoin, valproate 
RISK FOR HEAT STROKE (rare) 
Inhibition of carbonic anhydrase causes sweating inhibition 
Topiramate, zonisamide
PANCREATITIS (rare)8 
Unknown mechanism 
Valproate
Figure 3. Pharmacodynamics for antiepileptic safety.  
This figure is an update from Figure 3 in a prior article [28].  
1Drugs preceding ">" will produce this ADR more frequently than drugs following ">". 
2FGAEDs are associated with cognitive impairment in studies using neuropsychological testing.  
There are few neuropsychological studies on SGAEDs. Various authors agree that phenobarbital 
has the worst cognitive profile among FGAEDs, and topiramate among SGAEDs, but disagree on 
the relative impairment associated with specific compounds and how topiramate compares with 
FGAEDs. 
3They include diplopia and nistagmus. 
4Different reviews describe different frequencies for each AED-induced depression.  A 
comprehensive review described frequencies >10% for phenobarbital, primidone, topiramate and 
vigabatrin; 7% for zonisamide in high doses; ≤ 4% for felbamate, levetiracetam and tiagabine; and 
< 1% for the rest of the studied AEDs.  On the other hand, carbamazepine, lamotrigine, 
oxcarbazepine and valproate may have antidepressant properties in patients with epilepsy.   
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5It is difficult to assess when the psychosis is really an AED ADR rather than a manifestation of the 
underlying or associated illnesses. Studies using lamotrigine and topiramate in bipolar disorder do 
not describe increased psychotic symptoms.  
6It is difficult to assess when aggressive behavior is really an AED ADR rather than an underlying 
or associated illness. 
6There is general agreement in the literature that most drugs that cause torsade de pointes can be 
identified by assessing whether they block the human ether à gogo related gene (hERG) potassium 
channel and prolong the QT interval on the electrocardiogram, but it is not well understood why 
some drugs that block this channel do not cause torsades de pointes. Johannesen et al. [144] have 
proposed that drugs that at the same concentration that block the inward calcium or sodium 
channels they offset the pro-torsade effect of blocking the outward hERG potassium channels. 
7Brugada syndrome is identified by a specific ECG pattern (pseudo right bundle branch block and 
persistent ST elevation in leads V1 to V3) and high incidence of ventricular fibrillation in the 
absence of structural heart disease. Brugada syndrome is a channelopathy explained by genetic 
abnormalities in the cardiac sodium, potassium or calcium channels.  
8The literature describes valproate-induced pancreatitis as very rare. A comprehensive review in 
Germany indicated that milder cases are much more common than the literature suggests. 
Pancreatitis may be particularly frequent in facilities for adults with intellectual disabilities.  
ADR:  adverse drug reaction; AED: antiepileptic drug; common: ADR ≥10% in RCT; FGAED: 
first-generation antiepileptic drug; RTC: randomized clinical trial; SGAED: second-generation 
antiepileptic drug; SIADH: syndrome of inappropriate antidiuretic hormone. 
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PHARMACODYNAMICS FOR ANTIDEPRESSANT EFFICACY 
DEPRESSION1
Inhibitors of noradrenaline and serotonin transporter 
Desvenlafaxine, duloxetine, levomilnacipran, milnacipran (not approved in the US), TCAs, and venlafaxine 
Selective inhibitors of the serotonin transporter 
All SSRIs  
Selective inhibitors of the serotonin transporter and serotonin receptor antagonists2 
Vilazodone and vortioxetine 
Inhibitor of the noradrenaline and dopamine transporter2 
Bupropion 
Selective inhibitor of the noradrenaline transporter2 
Reboxetine (not approved in the US) 
5-HT2 antagonist (its major metabolite, m-CPP, is a 5-HT2C agonist) 
Trazodone 
α2 adrenergic receptor antagonist and/or 5-HT2A and 5-HT2C antagonist 
Mirtazapine 
Melatonergic analogue (MT1/MT2 agonist) and 5-HT2C antagonist 
Agomelatine (not approved in the US)
OCD 
Inhibitors of the serotonin transporter 
Chlorimipramine, SSRIs (not all are approved in the US2)
ANXIETY 
Same mechanism as antidepressant action3 
Different compounds are approved for different disorders4 but specificity is doubtful 
PAIN 
Inhibition of the noradrenaline transporter5 
TCAs are frequently used off-label 
Duloxetine and milnacipran are approved in the US for fibromyalgia 
Duloxetine is approved in the US for diabetic peripheral neuropathic and chronic musculoskeletal pain 
MIGRAINE PROPHYLAXIS (off-label in the US) 
Unknown mechanism 
TCAs (amitriptyline is the most studied), less data exists on venlafaxine 
WEIGHT LOSS 
Inhibition of the dopamine transporter 
Bupropion (off-label in the US)6 
SMOKING CESSATION 
Inhibition of the dopamine transporter 
Bupropion
ATTENTION DEFICIT HYPERACTVITY DISORDER 
Inhibition of the noradrenaline and dopamine transporter 
Bupropion (off-label in the US)7
INSOMNIA 
Antagonism of brain H1 receptors (daily sedation can be a problem) 
Amitriptyline, mirtazapine, trazodone (off-label in the US)  
Agonism of brain MT2 receptors 
Agomelatine (not approved in the US)
CATAPLEXY 
Suppression of REM sleep 
TCAs, venlafaxine (off-label in the US)   
SOME TYPES OF URINARY INCONTINENCE 
Noradrenergic mechanisms are important 
STRESS URINARY INCONTINENCE 
Duloxetine (off-label in the US)8 
NOCTURNAL ENURESIS IN CHILDREN 
Imipramine
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MENOPAUSAL VASOMOTOR SYMPTOMS (HOT FLASHES & NIGHT SWEATS) 
SNRIs, SSRIs (off-label in the US) 
Unknown mechanism 
Figure 4. Pharmacodynamics of efficacy for newer antidepressants. This figure is an update from 
Figure 1 in a prior article [33].  
1Textbooks usually report that the majority of antidepressants act by inhibiting reuptake 
transporters, but they also usually acknowledge that this is not a definitively proven theory, since 
the chronology of reuptake inhibition does not match the chronology of antidepressant response.  
2Vilazadone is described as a dual-acting serotonergic antidepressant that combines selective 5-HT 
reuptake inhibition with partial agonism of the 5-HT1A receptor. Vortioxetine is described as 
combining 5-HT reuptake inhibition with 5-HT3A and 5-HT7 receptor antagonism, 5-HT1B receptor 
partial agonism, 5-HT1A receptor agonism. 
3There are few attempts to describe the antidepressant pharmacological mechanism in anxiety 
disorders; the literature usually assumes that the various antidepressants work in anxiety using the 
same mechanism as in depression. 
4Fluoxetine, fluvoxamine, paroxetine and sertraline are approved in the US for OCD. SNRIs such 
as duloxetine, desvenlafaxine and venlafaxine are used off-label.  
4Duloxetine, escitalopram, paroxetine, and venlafaxine are approved for generalized anxiety in the 
US. Paroxetine, sertraline and venlafaxine are approved for social anxiety in the US. Paroxetine, 
sertraline and venlafaxine are approved for panic disorders in the US. TCAs are considered an 
effective off-label indication for panic disorder. A meta-analysis described the following newer 
antidepressants as significantly superior to placebo for panic disorder patients with the following 
increasing order of effectiveness: citalopram, sertraline, paroxetine, fluoxetine, and venlafaxine for 
panic symptoms and paroxetine, fluoxetine, fluvoxamine, citalopram, venlafaxine, and mirtazapine 
for overall anxiety symptoms. Aside from reboxetine and fluvoxamine, all drugs were associated 
with significantly lower dropout rates as compared with placebo. Based on a few agomelatine RCTs 
and uncontrolled studies, agomelatonine was considered a promising option when other 
pharmacological treatments had failed in anxiety disorders. Vortioxetine has had inconsistent 
results in generalized anxiety disorder RCTs. 
5It is believed that for pain treatment the inhibition of the norepinephrine transporter may be more 
important than the inhibition of the serotonin transporter. There are antidepressant RCTs in pain 
syndromes for fibromyalgia, painful diabetic neuropathy, postherpetic neuralgia, and neuropathic 
pain (or painful neuropathy). Although venlafaxine is not approved in the US for pain, some RCTs 
support its use. The benefits of duloxetine and milnacipran over placebo in fibromyalgia are small. 
6A meta-analysis indicated that weight loss with fluoxetine appears to be limited to the acute phase 
of treatment. The combination bupropion-naltrexone is being studied in RCTs for weight loss. 
7According to a meta-analysis, bupropion is superior to placebo and effective in adults. There is 
very limited data on other antidepressants. 
8Duloxetine can significantly improve the quality of life of patients with stress urinary incontinence, 
but it is unclear whether or not benefits are sustainable.  
5-HT: Serotonin receptor; α: Alpha adrenergic receptor; H: Histamine receptor; MT: Melatonin 
receptors; OCD: Obsessive-compulsive disorder; RCT: Randomized clinical trial; TCA: tricyclic 
antidepressant; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective serotonin  
reuptake inhibitor. 
56 
PHARMACODYNAMICS FOR ANTIDEPRESSANT SAFETY1 
BRAIN 
WEIGHT GAIN1 (common in long-term) 
Antagonism of brain H1  
(antagonism of other receptors  including M for TCAs and  5-HT2C for mirtazapine may contribute) 
Amitriptyline, mirtazapine, paroxetine  
↓ SEIZURE THRESHOLD (rarely relevant) 
Unknown mechanism 
Bupropion, TCAs>2placebo>2 some new antidepressants2,3 
DECREASED DOPAMINERGIC ACTIVITY 
Unknown mechanism 
Akathisia (rare) 
SSRIs 
Other extrapyramidal symptoms (rare) 
Probably all antidepressants4 
Hyperprolactinemia (rare) 
Probably all antidepressants5 
PSYCHOTIC EXACERBATION (rare)6
Inhibition of the dopamine transporter 
Bupropion 
Unknown mechanism 
TCAs 
INSOMNIA 
Different mechanisms7 
Present in newer antidepressants except for agomelatine 
PERIPHERAL (with/without brain component) 
NAUSEA AND VOMITING (common) 
Inhibition of the serotonin transporter8 
Desvenlafaxine, duloxetine and venlafaxine >2SSRIs, vilazodone, vortioxetine >2 levomilnacipran and milnacipran 
TACHYCARDIA and/or HYPERTENSION9 (relatively uncommon in RCTs) 
Inhibition of the noradrenaline transporter 
Desvenlafaxine, duloxetine (no hypertension), levomilnacipran, milnacipran, reboxetine, TCAs and venlafaxine 
ORTHOSTATIC HYPOTENSION (relatively uncommon when appropriately titrated) 
Antagonism of peripheral α1 receptors10 
TCAs, trazodone 
DIARRHEA (common) 
Unknown mechanism 
Sertraline,11 vilazodone and vortioxetine 
SEXUAL ADRs (common) 
Serotonergic mechanisms12 
TCAs, SNRIs, SSRIs 
Antagonism of peripheral α1 receptors 
PRIAPISM (very rare) 
Trazodone 
HYPERLIPIDEMIA 
Secondary to weight gain (see above) and direct effects on triglyceride levels 
Mirtazapine 
ANTICHOLINERGIC ADRs 
Antagonism of peripheral muscarinic receptors 
Tachycardia, constipation, dry mouth, urinary retention, blurred vision, ↓ sweating13   
TCAs > mirtazapine, paroxetine and possibly reboxetine 
Risk for heat stroke (rare but potentially lethal) 
TCAs 
URINARY SYMPTOMS (dysuria, urinary retention and sensation of incomplete bladder emptying) 
Noradrenergic mechanisms are important 
Desvenlafaxine, duloxetine, levomilnacipran, milnacipran, reboxetine and venlafaxine   
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MYDRIASIS (risk for uncontrolled narrow-angle glaucoma) 
Inhibition of the noradrenaline transporter 
Desvenlafaxine, duloxetine, levomilnacipran, milnacipran, reboxetine, TCAs and venlafaxine  
HYPERHIDROSIS (relatively uncommon) 
Peripheral noradrenergic and  central serotonergic mechanisms are important 
Probably all antidepressants    
OSTEOPOROSIS (after many years of treatment, making difficult to establish frequencies) 
Serotonergic mechanisms at bone tissue 
Probably SSRIs   
DISCONTINUATION/WITHDRAWAL SYNDROME   
Unknown mechanism 
Newer antidepressants: acute headaches, dizziness and nausea14 
Paroxetine and venlafaxine >2 other new >2 fluoxetine >2 agomelatine and reboxetine (absent) 
Cholinergic rebound 
TCAs: withdrawal symptoms after sudden discontinuation of high doses 
TCAs 
RISK FOR BLEEDING (rare but potentially lethal) 
Serotonin depletion in platelets due to inhibition of serotonin transporter and other mechanisms15  
SSRIs usually combined with other drugs with hemorrhagic risk or related to delivery or surgery 
SEROTONIN SYNDROME (rare but potentially lethal)  
Increased serotonin activity in brain and periphery 
Usually requires combinations of several drugs increasing serotonin activity 
ARRYTHMIAS  
Antagonism of heart channels 
QRS widening, QTc prolongation, and ventricular arrhythmias (relatively common in overdoses)  
TCAs 
Antagonism of heart repolarizing potassium channels 
Torsades de pointes (very rare)16  
Citalopram, fluoxetine, sertraline 
Risk for patients with Brugada syndrome17  
Antagonism of heart sodium, potassium or calcium channel 
Preferably avoid: fluoxetine, fluvoxamine and paroxetine 
NEUTROPENIA (rare) 
Unknown mechanism 
Mirtazapine 
HYPONATREMIA (rare, more frequent in geriatric females)  
SIADH and/or increase in ADH sensitivity18 
Probably all antidepressants 
LIVER INJURY 
Unknown mechanism 
Live enzyme elevations 
Agomelatine (up to 5% in 50 mg/day) >2 probably rare in other antidepressants  
Immune-allergic or toxic by metabolites 
Life-threatening liver injury 
Agomelatine >2 bupropion, duloxetine, TCAs, trazodone >2 other >2 citalopram, escitalopram, paroxetine and 
fluvoxamine 
Figure 5. Pharmacodynamics of safety antidepressants. 
This figure is an update from Figure 2 in a prior article [33].  
1The more comprehensive review comparing antidepressant safety and meta-analysis of RCTs did 
not include more recently marketed compounds. Agomelatine is a 5-HT2C antagonist. Insufficient 
data is available on long-term treatment to rule it out as a cause of weight gain. Case reports 
indicated some patients may gain significant weight with agomelatine long-term treatment.   
2Drugs preceding ">" will produce this ADR more frequently than drugs following ">". 
3A comprehensive literature review described bupropion as the only newer antidepressant 
associated with increased seizure risk in RCTs.  
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4Extrapyramidal symptoms have been reported with different classes of antidepressants, are not 
dose-related, and can develop with short-term or long-term use. 
5Symptomatic hyperprolactinemia has been reported with nearly all antidepressants. Incidence rates 
are not clearly established and symptoms were very rare.  
6The literature is somewhat contradictory but, in selected cases, bupropion and TCAs appear to be 
associated with the induction of psychotic symptoms, in addition to the precipitation or worsening 
of an existing psychotic syndrome.  
7Proposed mechanisms: 1) SSRIs may cause insomnia by 5-HT2 stimulation; 2) SNRIs and 
reboxetine may cause insomnia by blocking the noradrenaline transporter; and 3) mirtazapine may 
have a reverse-dose response effect with sedation at lower doses and with insomnia at higher doses. 
H1 antagonism is predominant at lower doses, while increased noradrenergic activity is 
predominant at higher doses.   
8Nausea and vomiting are the most frequent causes of discontinuation of newer antidepressants 
during the first 30 days of treatment. They are 10% more frequent in venlafaxine than in SSRIs.  
There are no comparisons of vilazodone and vortioxetine with other newer antidepressants. The 
estimate of the frequency of nausea is a rough estimate based on placebo-controlled RCTs. 
Mirtazapine and TCAs may help with some types of nausea.  
9In a comprehensive review comparing newer antidepressant safety, venlafaxine was significantly 
associated with hypertension when compared with other newer antidepressants. Desvenlafaxine and 
milnacipran also appear to cause hypertension.  Duloxetine has not been consistently associated 
with hypertension; increases in blood pressure have been mild, but caution should be used in 
patients with hypertension. Epidemiological studies have associated TCAs with hypertension.  
10Mirtazapine has very low affinity for α1 receptors and has rarely been associated with syncopes. 
Venlafaxine has no affinity for α1 receptors but has been consistently associated with orthostatic 
hypotension in geriatric patients. 
11Comprehensive reviews and meta-analyses agree that sertraline is associated with more diarrhea 
risk than other newer antidepressants.  
12It has been proposed that sexual ADRS may be related to serotonergic stimulation of 5-HT2 and 5-
HT3 receptors, but their origin is complex, probably also involving the effect of 5-HT on nitric 
oxide production as well as other systems.  Bupropion and mirtazapine may be no different than 
placebo. Agomelatine and reboxetine are probably associated with very low risk for sexual ADRs. 
Vilazodone appears to have low risk for sexual ADRs but is associated with more sexual ADRs 
than placebo. 
13Amitriptyline, clomipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine 
have definitive antimuscarinic activity. Amoxapine, desimipramine, maprotiline, mirtazapine and 
paroxetine have low antimuscarinic activity. Citalopram, escitalopram, fluoxetine, trazodone and 
sertraline show antimuscarinic activity in some studies but not in all. Reboxetine frequently causes 
dry mouth and constipation, and more rarely urinary retention. It has been proposed that the 
noradrenergic mechanism may explain these antimuscarinic symptoms because 1) reboxetine’s 
affinity for muscarinic receptors is too low to be relevant at therapeutic doses, and 2) no metabolites 
with greater antimuscarinic activity have been identified.  
14SSRI discontinuation included somatic symptoms such as dizziness, lethargy, and sleep 
disturbances, as well as psychological symptoms such as anxiety/agitation, irritability, and poor 
concentration. The literature provides very limited information on possible mechanisms. 
15It has been proposed that an SSRI-induced increase in gastric acid secretion may explain the 
gastrointestinal bleeding risk and that SSRI-related effects on platelet reactivity, endothelial 
reactivity, and inflammatory markers may explain the protective effect against ischemic heart 
disease. 
16A comprehensive literature review indicated that citalopram (8 cases), fluoxetine (6 cases) and 
sertraline (1 case) can rarely be associated with torsades de pointes. There is general agreement in 
the literature that most drugs that cause torsades de pointes can be identified by assessing whether 
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they block the human ether à gogo related gene (hERG) potassium channel and prolong the QT 
interval on the electrocardiogram, but it is not well understood why some drugs that block this 
channel do not cause torsades de pointes. Johannesen et al. [144] have proposed that drugs at the 
same concentration level that block the inward calcium or sodium channels also offset the pro-
torsade effect of blocking the outward hERG potassium channels.  
17Brugada syndrome is described in footnote 7 of Figure 3.  
18All antidepressants are probably able to cause hyponatremia on rare occasions. It usually happens 
in geriatric patients, particularly females. The literature usually describes these cases as SIADH but 
it is not clear why antidepressants can cause SIADH. 
5-HT: Serotonin receptor; ADR: Adverse drug reaction; common: ADR ≥ 10% in RCT; ECG: 
Electrocardiogram; H: Histamine receptor; M: Muscarinic receptor; TCA: Tricyclic antidepressant; 
RCT: Randomized clinical trial; SIADH: Syndrome of inappropriate antidiuretic hormone; SNRI: 
Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor.   
 
 
